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cancer is fundamentally a disease of imbalance in the regulation of cell proliferation. cellular 
proliferation is a tightly regulated process. several check mechanisms prevent the uncon-
trolled proliferation of cells. cancer cells have defects in the regulatory circuits that govern 
normal cell proliferation and homeostasis. the defects in these regulatory circuits are caused 
by genetic changes. 
the genetic changes through which cancer develops can be divided in two broad 
categories: changes in oncogenes and changes in tumor suppressor genes. Where oncogenes 
promote the malignant phenotype, tumor suppressor genes are genes which inhibit cell 
division, regulate survival or other properties of cancer cells. typically, changes in many 
genes are required to transform a normal cell into a cancer cell1,2, which may take many years 
to accumulate.
While there are many distinct types of cancer, there are believed to be six essential 
differences that set human malignancies apart form normal cell physiology1, self-sufciency 
in growth signals; insensitivity to growth-inhibitory signals, evasion of programmed cell 
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death (apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion 
and metastasis (gure 1, adopted from Keereweer et al.). Each of these so-called hallmarks is 
an acquired trait by genetic alterations in cancer cells and represents the successful ability of 
a tumor to evade the anti-cancer mechanisms present in cells and tissues.
the great majority of cancers occur in epithelial tissues (>80%), yielding carcinomas3, 4. 
in the development of epithelial cancer, roughly, several phases can be distinguished (gure 
2, adapted from the national cancer institute). hyperplasia is a reversible proliferation of cells 
beyond that which is ordinarily seen. hyperplastic cells remain subject to normal regulatory 
control mechanisms. Dysplasia is the earliest form of pre-cancerous lesion and can be divided 
into low or high-grade dysplasia, where high-grade dysplasia represents a more advanced 
progression towards malignant transformation. a carcinoma in situ is a localized form of 
cancer which has not invaded past the basement membrane into surrounding tissues. the 
cells in a carcinoma in situ grow rapidly and without regulation. the nal step is an invasive 
carcinoma which has the potential to metastasize. 
Figure 2
2. Tumor progression
2.1 role of the tumor miCroenvironment
cancer has long been regarded a disease consisting of a group of transformed cells which 
have acquired proliferative and invasive capacities. accordingly, therapeutic anti-cancer 
therapies have been concentrated on and limited to targeting tumor cells alone (see also 
chapter 3). in order for cancer to be effectively controlled, carcinogenesis and tumor progres-
sion needs to be viewed involving complex interactions with its environment; the tumor 
microenvironment. currently, more and more data indicate that we need to revise our ideas 
on carcinogenesis and carcinomas and regard these as phenomena that occur in tissues, not 
just in cancer cells. 
the development of a tumor takes place in an environment that consists of a 
complex system containing many different cell types. the tumor microenvironment 
contains endothelial cells and their precursors, pericytes, smooth muscle cells, broblasts of 
various phenotypes, myobroblasts, neutrophils and other granulocytes (eosinophils and 
basophils), mast cells (mcs), t, b, and natural killer lymphocytes and antigen presenting cells 
such as macrophages and dendritic cells. all these cells can in one way or another participate 
in tumor progression. 
for example, experiments in mouse models have shown that broblasts in the 
stromal microenvironment play an important role in tumor formation5-7. next to this, cancer-
associated broblasts (cafs) have been shown to induce tumorigenesis in prostatic epithelial 
cells8. moreover, cafs have been shown to be able to promote tumor growth and increase 
angiogenesis9-10. furthermore, myobroblasts, also known as activated broblasts, constitute 
an important niche for tumor development through the promotion of angiogenesis11-13. 
the presence of leucocytes in tumor tissues was until late thought to be an attempt 
of the immune system to eradicate the tumor. this idea needs to be revised. it has been 
shown that leukocyte cells such as macrophages, granulocytes and mast cells all have been 
associated in one way or another with promotion of malignancy. tumor-associated 
leucocytes are variably loaded with an assorted array of cytokines, cytotoxic mediators as 
well as proteolytic enzymes that promote all the steps associated with malignancy within 
tumors14-16. 
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the role of granulocytes has been extensively studied with contradictory results. for 
example, it has been shown that circulating neutrophilic polymorphonuclear cells (pmns) iso-
lated from tumor bearing animals reduce the number of metastatic foci in the lungs17. on the 
other hand, in vitro studies reveal that pmns stimulate tumor cell attachment to endothelial 
monolayers, a relevant step for tumor migration18, 19. next to this, neutrophylic granulocytes 
have also been shown to promote the migratory capacity in breast cancer cells20. other 
authors have shown that tumor-associated pmns were involved in tumor angiogenesis by the 
production of vascular endothelial growth factor (VEGf) and interleukin (il)-8 and in tumor 
invasion by the release of matrix metalloproteinases (mmps) and elastase21-23.
figure 3 (adapted from albini et al.) illustrates the sequence of events and involve-
ment of the tumor microenvironment during carcinogenesis24. a current concept of tumor 
progression and interaction with the microenvironment is that it roughly resembles an 
inammatory process. the transformation taking place during tumorigenesis may lead to 
disrupted proliferation. this disruption is regarded as cell damage and causes an inammatory 
reaction, in order to repair and reconstruct the damaged lesion. this inammatory reaction 
includes leukocyte inltration and stromal and endothelial cell activation. this alteration of 
tissue homeostasis further promotes tumor progression, which in turn further activates the 
surrounding stroma, eventually also leading to neovacularization, or tumor angiogenesis, 
which is a critical step in the further progression, invasion and metastasis of a tumor. as such, 
in fact, a reaction to restore the damage caused by the tissue transformation, paradoxically 
results in further promoting the progression, survival and replication of the dysfunctional 
epithelial cells. 
2.2 tumor angiogenesis
angiogenesis is an essential and critical step in the further progression, invasion and 
metastasis of a tumor. angiogenesis, the formation of new blood vessels from pre-existing 
vasculature, is dependent on a balance between pro- and anti-angiogenic factors. anti- 
angiogenic factors predominate in tissues where the vasculature is quiescent. in contrast, 
when the balance is in favor of pro-angiogenic factors, angiogenesis is promoted. for a tumor 
to grow beyond a certain size there is a need for nutrients, oxygen and the efcient remo-
val of waste product by acquiring its own vasculature through angiogenesis. this onset of 
angiogenesis during tumor progression is called the 'angiogenic switch' as rst postulated 
by folkman25. this requirement may vary, however, among tumor types and change over 
the course of tumor progression26, 27, but gaining access to the host vascular system and the 
generation of a tumor blood supply are rate-limiting steps in tumor progression. 
in normal physiological angiogenesis there is a tightly regulated balance of pro- and 
anti-angiogenic signals, which results in rapid maturation and stabilization of newly for-
med microvasculature if the balance is in favor of pro-angiogenic factors. in tumor angio-
genesis, this process is incomplete and cut short, leading to formation of tumor vessels that 
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disorganized, tortuous and spatial distribution overall is heterogeneous. also, tumor vas-
culature spreads without any organization, is irregularly shaped, dilated, leaky, and poorly 
differentiated. tumor vessels may have thin walls, with only partial endothelial linings, loss 
of adherence between endothelial junctions, loosely attached or absent perivascular cells 
and a discontinuous basement membrane27-31. further to this, it has even been observed that 
tumor cells in certain circumstances may undergo a dedifferentiation program, leading 
them to act as endothelial cells and line the tumor vasculature themselves32-34. the concept of 
selectively targeting tumor vasculature in anti-angiogenesis therapy without affecting the 
quiescent organ vasculature is based on the phenotype of immature angiogenic blood vessels 
being distinctly different from that of normal and resting blood vessels. 
as described above, the tumor microenvironment plays an important role in the 
onset and activation of tumor angiogenesis because of the alteration of surrounding 
tissue homeostasis. likewise, tumor cells acquire certain specic genetic traits allowing the 
onset and progression of tumor angiogenesis. During tumor angiogenesis, pro-angiogenic 
factors are upregulated, and anti-angiogenic factors downregulated by both the tumor cells 
themselves as in the tumor microenvironment. numerous of such endogenous pro- and 
anti-angiogenic factors have been identied, such as the pro-angiogenic factor VEGf-a, 
member of a gene family that further includes placental growth factor (plGf), VEGf-b, 
VEGf-c, VEGf-D and VEGf-E. other pro-angiogenic factors include broblast growth factors 
(fGfs), angiopoetins, platelet-derived growth factors (pDGfs), transforming growth factor- 
beta (tGf-β) and many others. anti-angiogenic factors include, among many others, 
thrombospondins35, endostatin (a proteolytic cleavage product of collagen xViii)36, and 
soluble factors like interferon-α and -β (ifn-α and -β) and angiostatin37. 
both pro- as anti-angiogenic factors can be regulated and derived from both the 
tumorcells themselves as from tumor-inltrating inammatory cells. as such, the angiogenic 
switch is an intrinsic event of multistage tumorigenesis where genetic and epigenetic events 
within tumor cells cooperate with inammatory responses and cells of the tumor stroma 
to dene the ultimate cocktail of pro- and anti-angiogenic factors. this results in a direct or 
indirect shift of the balance in favor of an onset of tumor angiogenesis37.
the importance of tumor-stroma interactions with concurrent angiogenesis and 
tumorigenesis and tumor progression has been widely recognized. the question that remains 
is which comes rst: the dysfunction of epithelial cells or the changes in their microenvi-
ronment? for example, it has been shown that transformed stroma can induce malignancy 
in lung and mammary epithelia5, 6. moreover, taken the above into account one has to ask 
whether tumorigenesis and progression can occur because, instead of despite, of the tumor 
microenvironment. one way or another, because the role of the different players in the tumor 
microenvironment is now beginning to become known, they need to be and are now coming 
into the picture as targets for anti-tumor therapy.
2.3 tumor metastasis
further along the way in tumor development and progression, tumor cells may acquire 
invasive properties and further on acquire the ability to metastasize. in order for a tumor 
cell to metastasize, it needs to acquire the ability to migrate and invade. migratory cancer 
cells undergo dramatic molecular and cellular changes by remodeling their cell-cell and 
cell-matrix adhesion and their actin cytoskeleton, molecular processes that involve the 
activity of various signaling networks. metastasis formation is driven by genetic alteration 
of many genes, such as the activation of oncogenes like ras and myc38, 39 and inactivation 
of metastasis-suppressor genes such as p53 and nm2340, 41. further to this, the metastasizing 
tumor cells need to be able to adapt to and survive and grow in a new environment. 
next to this, the metastasis site itself needs to have the right environmental 
properties for the tumor cell to thrive. the theory that metastasis is not just dependent on 
the acquired traits of the tumor cell at stake, but also dependent on the properties of the 
metastatic niche is called the 'seed and soil' hypothesis and was postulated by stephan paget 
more than a century ago42. 
the 'seed and soil' hypothesis was based on the observation that certain tumors 
metastasize to certain sites, i.e. tumors do not metastasize randomly. for example, breast 
cancer and prostate cancer is most likely to metastasize to bone tissue, malignant melanoma 
has a tendency to metastasize to the brain, whereas colon cancer has the liver as a preferred 
secondary site. as well as during primary tumor development, the microenvironment of the 
secondary site plays a major role in metastasis, survival and progression.
it is thought that the specic secondary sites contain the microenvironment with 
specic local molecular mediators as to support the suitable type of cancer cells. this 
concept still holds ground to this day. breast cancer for example, frequently metastasizes to 
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the skeleton. it is estimated that 85% of individuals with advanced breast cancer disease have 
bone metastases43. When metastasizing to bone, breast cancer cells rst come into contact 
with the bone marrow inside the bone, through circulation in blood (hematogenous spread). 
it has been shown that the bone marrow is particularly favorable for the retention and 
extravasation of circulating cancer cells44. moreover, the bone itself is an abundant storage of 
growth factors. mineralized bone contains insulin growth factors (iGfs), tGf-β, fGfs, pDGfs 
and bone morphogenetic proteins (bmps), which are constantly released in the bone marrow 
through osteoclastic bone resorption, further positively affecting the growth of the local bone 
metastases45, 46. 
further major components of mineralized bone further are osteopontin (opn), bone 
sialoprotein (bsp) and type i collagen, which all help mediate local adhesion, motility, survival 
and growth by interactions with matrix molecules such as integrins, of which αvβ3 and αiiβ3 
integrins seem to participate in determining the osteotropism of breast cancer metastases47, 
48. it has been shown for example, that the breast cancer cell line mDa-mb-231-b02, a subclone 
of cell line mDa-mb231, which constitutively overexpresses αvβ3 integrin only metastasizes 
to bone. similarly, de novo expression of αvβ3 integrin in a breast cancer cell line that would 
normally metastasize to the lungs, showed to promote its dissemination to bone49, 50. 
With regard to the intrinsic properties of breast cancer cells, it has been shown that 
breast cancer cells at one point in time express genes that are normally considered bone or 
bone-related and as such preferentially metastasize to bone. in expressing these genes, the 
breast cancer cells are well equipped to home, adhere, survive and proliferate in the bone 
microenvironment. this acquisition of bone cell-like properties by tumor cells is called 
osteomimicry51. osteomimetic factors for example include opn, osteocalcin, osteonectin, bsp, 
receptor activator of nuclear factor kappa b ligand (ranKl) and parathyroid hormone-related 
protein (pthrp). several of these molecules are related to the recruitment and differentiation 
of osteoclasts. for example, opn is produced by many breast cancer cells and has a strong 
clinical correlation with poor prognosis and decreased survival51-53. it can contribute to tu-
mor cell survival, proliferation, adhesion, and migration. in the bone, opn is involved in the 
differentiation and activity of osteoclasts, and inhibition of mineral deposition in the 
osteoid52. 
so, taken together, as well as during tumorigenesis and tumor progression, in 
metastasis both the tumor microenvironment as the cancer cells themselves are well 
equipped, suited even, for the event. it has been hypothesized that cancer cells, which are 
metastatic to bone after an initial growth phase that depends on their interaction with the 
local stroma, become independent of microenvironment's growth support and further 
progress autonomously54. this was postulated after the observation that decrease of bone 
turnover by bisphosphonates (bone resorption decreasing agents) before colonization of 
bone by breast cancer cells, inhibits to a great extent the formation of bone metastases, but 
when bisphosphonate treatment was given after the establishment of bone metastases, it 
was shown to have a minimal effect on the progression of cancer growth54, 55.
2.4 the prinCiples of Darwinian evolution in CanCer
it has not been for long that it is recognized that tumor progression actually follows the 
principles of Darwinian evolution. this process is called somatic evolution. a tumor is a large 
genetically heterogeneous population of individual cells. cells that acquire traits through 
genetic changes that enhance their survival or reproduction continue to multiply, and come 
to dominate the growing tumor, thereby promoting tumorigenesis. this process leads to 
the clonal expansion of the cells with favorable properties. clonal expansion and genetic 
heterogeneity has been observed within many different types of neoplasms and the idea of 
Darwinian evolution within cancer is now an accepted concept56.
the process of somatic evolution is not just important during tumorigenesis. it 
also allows the tumor to react to its environment in an adaptive manner. this has large 
consequences for the ability of the tumor to progress and metastasize, but also for its ability 
to react to cancer therapy. for the ability of a tumor to metastasize, the metastatic phenotype 
needs to be acquired by genetic alteration, but the tumor also needs to be able to survive 
and adapt in a new environment. this asks for a highly adaptive phenotype, one which can 
only be acquired by genetic favorable changes. this adaptive phenotype is not only largely 
important in the start, progression and metastasis of a tumor, but also has large implications 
in the phenomenon of 'acquired drug resistance' in anti-cancer therapy as further described 
below. 
this principle of somatic evolution in cancer ts the current explorations on the 
concept of cancer stem cells. Even though still debated upon, some evidence indicates the 
existence of self-renewing stem/progenitor-like tumor cells, so-called cancer stem cells 
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(csc's), which are critical for initiation and maintenance of the primary tumor and eventually 
metastasis. it is believed that both the tumor cells themselves as environmental factors 
induce some cancer cells to dedifferentiate to acquire stem cell like properties. in carci-
nomas it has been shown that cancer cells can lose their epithelial characteristics via a 
dedifferentiation process called the epithelial mesenchymal transition (Emt), which causes 
them to functionally transition to migratory matrix molecules producing mesenchymal cells. 
functional dedifferentiation gives these cells the ability to adapt to all sorts of different 
situations and surroundings and have a major role in the promotion of tumor invasion, 
angiogenesis, intravasation and different processes during metastasis such as dissemination, 
colonization and formation57. further to this, it has been shown that chemotherapy generally 
target cells with a more differentiated phenotype and thus indirectly selecting tumor cells 
with adaptive stem/progenitor phenotypes58. 
3. Tumor therapy
3.1 Conventional tumor therapy: Chemo monotherapy anD Drug resistanCe
cancer is one of the leading causes of death worldwide (data from the World health 
organization). Deaths from cancer worldwide are projected to continue rising, with an 
estimated 12 million deaths in 2030. for this reason, the development of new and improved 
anti-cancer therapies is of large social importance, with in the future ideally resulting in 
cancer to be a chronic disease at most.
to date, one of the most commonly used therapies still remains chemotherapy. the 
era of chemotherapy began in the 1940s, with the rst use of nitrogen mustard as an anti- 
cancer treatment by louis Goodman and alfred Gilman in 1942. a patient with non-hodgkin's 
lymphoma was treated with this toxin, based on autopsy ndings in soldiers dying of 
exposure to sulphur mustard gas during the first World War. these victims showed 
pronounced lymphoid hypoplasia and myelosuppression, leading to the proposal that these 
reagents may be used to counteract lymphoid tumors. the treated patient showed regression 
of the disease for a few weeks, establishing the principle of systemic drug administration 
to induce tumor regression. follow-up drugs soon came into the picture, such as alkylating 
agents (e.g. cyclophosphamide) and antifolates (e.g. methotrexate). it was soon noted that 
tumors quickly became resistant to these drugs, which was an observation that predicted 
clinical experience with these agents up to the present59, 60.
therapeutic resistance can either be caused by intrinsic resistance, or by acquired 
drug resistance, which is the ability of the tumor cells to adapt to the given therapy by an 
evolutionary process. Depending on the sort of therapy, the type of cancer, and its stage, 
one or several genetic alterations are necessary to confer resistance to treatment. some 
mechanisms of resistance require two genetic alterations, either because of haplosufciency 
of a gene such that one recessive mutation cannot confer resistance, or because of the use of 
combination therapy that targets two different positions in the cancer genome. one of the rst 
discovered genetic alterations leading to acquired therapy resistance was in methotrexate. 
this chemotherapeutic agent inhibits the dihydrofolate reductase (Dhfr) gene. however, 
methotrexate therapy appeared to select for cells with extra copies of the Dhfr gene, which 
are resistant to methotrexate61-65. the observation of chemotherapeutic drug resistance soon 
led to the idea to use combinations of drugs, each with a different mechanism of action.
3.2 Conventional tumor therapy: 
Combination Chemotherapy anD multi-Drug resistanCe
because of the observed drug resistance, it was hypothesized that cancer cells could 
conceivably mutate to become resistant to a single agent, but that by using different drugs 
concurrently it would be more difcult for the tumor to develop resistance. this approach 
was rst successfully applied by holland, freireich, and frei, who simultaneously adminis-
tered methotrexate (an antifolate), vincristine (a vinca alkaloid), 6-mercaptopurine (6-mp) 
and prednisone in children with acute lymphoblastic leukaemia (all), thereby inducing 
longtime remission59, 60. With incremental renements of original regimens, all in children 
has now become a largely curable disease. currently, nearly all successful cancer chemotherapy 
regimens use this paradigm of multiple drugs given simultaneously.
combination chemotherapy was devised to overcome resistance, by treating with 
agents that exert their effects by different mechanisms and/or are very different chemically. 
Unfortunately, it was soon observed that cancer cell populations can respond by becoming 
multi-drug resistant (mDr) to a panel of mechanistically and structurally diverse drugs. 
resistant and mDr cell variants within tumors which are either inherently present or 
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Figure 4
generated may be selected, in a Darwinian fashion, during multiple cycles of chemotherapy. 
of course, many chemotherapeutic agents are mutagenic, thus also increasing the frequency 
of resistant mutants in the cancer cell population.
molecular mechanisms of drug resistance include overexpression of drug efux 
pumps (generally atp-binding cassette [abc] transporter family members), such as the 
mdr-1 gene product p-glycoprotein (p-gp)/p-170 (abcb1), multi-drug resistant associated 
protein-1 (mrp-1; abcc1) and related proteins, and breast cancer resistance protein (bcrp; 
abcG2). the three key mammalian transporters involved in transport of anti-cancer agents, 
such as the anthracyclines, are p-gp, mrp-1 and bcrp66, 67. 
in recent years, much effort has been made to identify agents that are able to 
overcome mDr, in order to improve chemotherapeutic treatment. these agents, called 
chemosensitizers, belong to a variety of structural classes, such as calcium channel blockers, 
drug analogs, cyclic peptides and steroids68, 69. next to that, other therapeutic options in order 
to improve treatment benet and overcoming the tumor's ability to escape therapy are being 
explored as further discussed below.
3.3 Chemopreventive tumor therapy; anti-angiogenesis therapy
the limitations of chemotherapy have led to the exploration of therapies with improved 
efcacy, amongst others chemopreventive approaches. cancer chemoprevention, as rst 
dened by sporn in 1976, is dened as the use of natural, synthetic, or biologic chemical 
agents to reverse, suppress, or prevent carcinogenic progression to invasive cancer70. it is 
based on the concepts of multistep carcinogenesis. arresting one or several of these steps 
before cells are developing in tumorigenesis may then interfere with the disease's progression. 
Denitions of chemopreventive agents have become blurred a bit over time, because it 
has become clear that many chemopreventive agents not just have preventive effects by 
interfering with different stages during a tumor's development, but also have direct inhibi-
tory effects on already established tumors or its microenvironment. one way or another, this 
eld is extensively being explored and in some occasions used with positive effects in the 
clinical setting. cancer chemoprevention may comprise of different approaches, of which 
some are shown in gure 4 (adapted from soria J.c. et al.)71. 
one chemopreventive approach in anti-cancer therapy which is and has extensively 
been explored is anti-angiogenesis therapy. as stated above, in general, for a tumor to grow 
beyond a certain size there is a need for nutrients, oxygen and the efcient removal of waste 
product by acquiring its own vasculature through angiogenesis. this process is essential for 
the growth of solid tumors and facilitates metastasis, thereby providing a rationale for 
anti-angiogenesis therapy in cancer72, 73. tumor angiogenesis can be inhibited by endogenous 
anti-angiogenic factors, which results in inhibition or even regression of tumor growth and 
metastasis74. 
one of the rst endogenous anti-angiogenic factors to be explored was endostatin75. 
Endostatin is a cleavage product of collagen xViii that has shown to inhibit tumor- 
angiogenesis in experimental tumor models. several studies have shown the inhibition of 
endothelial cell proliferation and migration and endothelial cell apoptosis in vitro76-80, and 
growth of tumors and metastases in vivo81-83. in animals, endostatin causes tumor vessels 
to collapse, which leads to the deprivation of oxygen and nutrients and results in apoptosis 
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and necrosis of the tumor cells84, 85. no toxic side effects have been observed76, 79 and systemic 
therapy has not shown to be associated with acquired resistance86. Where results of 
preclinical studies on endostatin were promising, however, the rst phase i clinical trials were 
disappointing87-89. although endostatin showed no treatment-related toxicity, no signicant 
anti-tumor effect was observed. in one study a reduction in tumor blood ow and metabolism 
and an increase in apoptosis in tumor and endothelial cells was observed. however, no 
signicant relationship between these biological markers and clinical outcome could be 
established90. clinical trials with endostatin are however currently ongoing (data from 
clinicaltrials.gov).
as recently in the news, other examples of chemopreventive agents are non-steroidal 
anti-inammatory drugs (nsaiDs) and specic cyclo-oxygenase (cox)-2 inhibitors, which 
are widely used in the treatment of pain and rheumatoid arthritis. a recent meta-analysis 
showed that daily use of the nsaiD aspirin signicantly reduced deaths due to several 
common cancers during and after the trials91. nsaiDs and cox-2 inhibitors both have shown 
promising results in the treatment of cancer in experimental and clinical studies92, 93. cox-2 
is overexpressed in many malignancies and is involved in tumor development and growth. 
the effects of nsaiDs and specic cox-2 inhibitors on tumor cells include inhibition of cell 
proliferation, induction of apoptosis and reduction of cell motility and adhesion93-101. further-
more, both non-specic and specic cox-2 inhibitors have shown to signicantly inhibit 
tumor angiogenesis102-105. moreover, combining nsaiDs and specic cox-2 inhibitors with 
chemotherapeutics has been shown to improve treatment outcome in several preclinical 
and clinical studies. for example, in experimental and clinical studies, the cox-2 inhibitor 
celecoxib, has shown to enhance the anti-tumor efcacy of several cytostatics, such as that of 
irinotecan, doxorubicin, bleomycin and 5-uorouracil106-109.
overall, despite promising results in preclinical studies in which anti-angiogenic 
therapy translates into potent anti-tumor effects110-119, implementation of these therapies in 
clinical settings has learned that benecial effects in the patient are less pronounced. one 
of the explanations for this may be that tumors grow in well vascularized tissues and they 
may progress via increased reliance on vessel co-option from the microenvironment. as 
anti-angiogenic compounds do not affect incorporated pre-existent, or matured tumor 
vasculature, targeting of the existing tumor vessels may be an attractive adjuvant approach 
to accomplish tumor regression via disruption of the tumor's blood supply.
3.4 vasCular targeting
next to targeting angiogenesis, another approach to target the tumor's blood vessel net-
work exists, aiming to affect the already established tumor vasculature120. the preferential 
targeting of the already established tumor vascular network and makes use of so-called 
vascular-disruptive agents (VDas)121-123. all VDas currently examined draw on the differences 
between tumor and healthy vasculature to allow for highly selective targeting of tumor blood 
vessels124, 125. the VDas can be divided into two categories: biologic and small-molecule agents. 
Where the rst includes peptides and antibodies that deliver effectors to the tumor endothe-
lium, the latter includes compounds that exploit the differences between healthy and tumor 
vasculature to induce selective vascular dysfunction126-128. 
because of the difference between targeting angiogenesis and the existing vas-
cular network, both could have their role in anti-cancer therapy. Where anti-angiogenesis 
treatment is thought to be well-suited for treating micrometastatic disease and early-stage 
cancer, disrupting established tumor vasculature leads to rapid vascular collapse, vessel con-
gestion and tumor necrosis and is therefore more efcacious against large, already established 
tumors. both approaches have shown promising results in ongoing preclinical studies, but 
treatments either targeting tumor-angiogenesis or established tumor vasculature alone has 
not yet shown to be fully effective124, 129-133. 
Effective targeting of tumor endothelium requires the availability of tumor-vessel 
specic targeting agents or VDas with high enough specicity for existing tumor vascula-
ture. few candidate VDas have been identied so far. this is, however, also due to the lack of 
adequate screening methods which are able to identify efcacy of candidate drugs and also 
discriminate between the different vascular targets. 
3.5 exploring the tumor miCroenvironment as anti-CanCer target
because of the remaining therapeutic gaps in the treatment of cancer and limitations of 
clinical therapies, research is ongoing to identify suitable drugs and targets in anti-cancer 
treatment. as stated above, the tumor microenvironment plays a large role in tumorigene-
sis, tumor progression, migration, invasion and eventually metastasis. as such, this has led 
researchers currently exploring the microenvironment as an anti-cancer target. it is im-
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portant to recognize that therapeutic targets can be sought in both the environment of the 
developing tumor, as in the secondary microenvironment site in case of metastasis. 
as the microenvironment has such a crucial role in carcinogenesis and metastasis, 
it represents a crucial target not only for cancer therapy but also for chemopreventive 
strategies as further elaborated on above. there is already a large amount of information 
about specic cells and molecules in the tumor microenvironment that are targets for can-
cer therapy at present134, 135. the supporting players in the tumor microenvironment include 
stromal broblasts, inltrating immune cells, the blood and lymphatic vascular networks, 
and the extracellular matrix. figure 5, (as adapted from mueller m.m. et al)133 shows the 
different players in the stromal compartment of a developing primary tumor. there is abun-
dant evidence that an abnormal stromal context contributes to, or is even required for, tumor 
formation and progression. 'normalization' of the stromal environment should therefore be 
able to slow or even reverse tumor progression136-138. 
the potential of a normal context to suppress a tumorigenic phenotype has been 
shown in different experimental settings. for example it has been demonstrated that the 
presence of a reconstituted physiological basement membrane induces pre-malignant breast 
epithelial cells to undergo growth arrest and form polarized alveolar structures, as normal 
epithelial cells would139. this normalization is in part mediated by integrins, as blockade of 
signaling by β1-integrin reverted tumorigenesis despite maintained genetic abnormalities in 
the epithelial cells140.
potential therapeutic target components of the tumor microenvironment in-
clude stromal cells such as endothelial cells, tumor associated broblasts, macrophages, 
extracellular matrix (Ecm) molecules such as thrombospondin and bronectin (fn), 
matrix-degrading proteases and inhibitors such as matrix metalloproteinases (mmps) and 
tissue metalloproteinase inhibitors (timps) and regulatory molecules such as integrins, 
growth factors and chemokines134. these agents may provide an interesting alternative to 
traditional tumor cell-directed therapy141. because of the complexity of the tumor milieu, the 
most benecial therapy will likely involve the combination of one or more agents directed at 
this new target. advantages to targeting the stroma include the fact that these cells are not as 
genetically unstable as cancer cells, and are therefore less likely to develop drug resistance142, 
143. several success stories of drugs that target the tumor microenvironment have entered the 
clinic134, 135.
in discussing targeting the tumor microenvironment, we should also consider the en-
vironmental conditions in which metastatic tumors develop. as discussed above, metastatic 
cells need an appropriate microenvironment in which they can survive and proliferate. While 
experimental systems have shown that tumor cells arrive at secondary sites at relatively 
high rates, they only thrive in certain, stereotypical sites42, 144, 145. as such, next to targeting the 
microenvironment of the developing tumor, the molecular microenvironment of successful 
metastasis sites is a promising target for interfering with either the homing or the survival 
of metastatic cells.
one example of an important advance in this direction came from the discovery of 
two highly expressed chemokine receptors (cxcr4 and ccr7) on metastatic breast cancer 
cells. their respective ligands (cxcl12 and ccl21) were preferentially expressed in the lung 
and regional lymph nodes, two important metastasis sites. When the interaction between 
one of these pairs (cxcl12/cxcr4) was blocked in vivo using neutralizing antibodies, there 
was a signicant reduction in breast cancer metastases to both the lung and lymph nodes146. 
inhibitors of chemokines and their receptors are in preclinical development and may offer a 
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means to interfere with the homing of tumor cells to secondary organs147. another approach 
is targeting the progression or establishment of metastases by preventing the growth in the 
secondary site. this has been explored by administration of bisphosphonates (bone resorp-
tion decreasing agents) before colonization of bone by breast cancer cells, which was shown 
to inhibit to a great extent the formation of bone metastases47.
4. Outline of this thesis
because of existing therapeutic gaps in the treatment of cancer and cancer remaining one of 
the leading causes of death worldwide, the development of new and improved anti-cancer 
therapies is of large importance. in doing so, it is of vital importance, not just to enhance and 
improve existing therapies, but also to explore new therapeutic options such as chemopre-
ventive agents, vascular disruptive agents and approaches interfering with the tumor mi-
croenvironment. furthermore, it is important to understand the effect of these treatments on 
a genetic level and in doing so identify new possible therapeutic options in aforementioned 
targets. 
in chapter 2 of this thesis we studied the differential gene expression in a human 
renal cell carcinoma model after treatment with the chemopreventive anti-angiogenic agent 
endostatin. Chapter 3 describes the setup and validation of a new screening model which 
is able to identify and discriminate between possible new anti-angiogenic drugs and the 
currently developed and investigated vascular disruptive agents. Chapter 4 and 5 describe 
the application of two different combination approaches in anti-cancer therapy which are 
currently extensively explored. Where chapter 4 describes the combinational therapy of the 
chemotherapeutic agent doxorubicin and the chemopreventive cox-2 inhibitor celecoxib, 
chapter 5 studies the effects of the combinational therapy of the chemotherapeutic agent 
docetaxel with the bisphosphonate risedronate on breast cancer bone metastases. finally, 
general conclusions and discussions are described in chapter 6.
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Abstract
Endostatin is a cleavage product of collagen xViii that has shown to inhibit tumor- 
angiogenesis in experimental tumor models. at present, the exact molecular mechanism of 
action of endostatin is not completely elucidated. in this study, we wanted to identify specic 
target genes of endostatin. for this purpose, the human renal cell carcinoma rc-9 was subcuta- 
neously implanted in nude mice and treated with endostatin. tumor growth was inhibited 
by endostatin after 4 days of treatment. Using immunohistochemistry and the hypoxia 
marker pimonidazole, we demonstrate disintegration of blood vessels and hypoxia and 
anoxia as a result of the treatment. hereafter, we applied the polymerase chain reaction 
(pcr)-based subtractive suppression hybridization (ssh) method, together with the mir-
ror orientation selection (mos) technique to identify specically induced and suppressed 
genes after endostatin-treatment. We found eight genes to be specically induced and 11 
to be suppressed by the endostatin-treatment. among other genes, core binding factor a-1/ 
osteoblast-specic factor-2 (cbfa1/osf2) was found to be specically suppressed by endosta-
tin. Unexpectedly, cbfa1/osf2 was found to be specically expressed in granulocytes in the 
tumor, not only in the experimental rc- 9 tumor model, but in sections of human breast 
cancer as well. since an effect of anti-angiogenic therapy on granulocytes has been reported 
before, this might lead to new insights in the role of granulocytes in anti-angiogenic therapy 
in general. in conclusion, the ssh-pcr implemented with the mos-technique is a powerful 
tool to identify differentially expressed genes. Using these techniques, we have identied 
several target genes of endostatin, of which cbfa1/osf2 was found to be specically expressed 
in granulocytes in the tumor. 
Introduction
angiogenesis, the formation of new blood vessels from pre-existing vasculature, is 
dependent on a balance between pro- and anti-angiogenic factors. anti-angiogenic factors 
predominate in tissues where the vasculature is quiescent. in contrast, when the balance 
is in favor of proangiogenic factors, angiogenesis is promoted. this process is essential for 
the growth of solid tumors and facilitates metastasis, thereby providing a rationale for 
anti-angiogenesis therapy in cancer1,2 tumor angiogenesis can be inhibited by endogenous 
anti-angiogenic factors, which results in inhibition or even regression of tumor growth and 
metastasis in animals.3 one of these factors is endostatin.4 
Endostatin is a cleavage product of collagen xViii that has shown to inhibit tumor-
angiogenesis in experimental tumor models. several studies have shown the inhibition of 
endothelial cell proliferation and migration and endothelial cell apoptosis in vitro,48 and 
growth of tumors and metastases in vivo.911 in animals, endostatin causes tumor vessels to 
collapse, which leads to the deprivation of oxygen and nutrients and results in apoptosis and 
necrosis of the tumor cells.12,13 no toxic side effects have been observed4,7 and systemic therapy 
has not shown to be associated with acquired resistance.14 
the results of preclinical studies on endostatin have been promising; however, the 
rst phase i clinical trials have been disappointing.1517 although endostatin showed no treat-
ment-related toxicity, no signicant anti-tumor effect was observed. in one study, a reduction 
in tumor blood ow and metabolism and an increase in apoptosis in tumor and endothelial 
cells was observed. however, no signicant relationship between these biological markers 
and clinical outcome could be established. 18 further preclinical studies on endostatin may 
lead to a better understanding of its mechanism of action and may lead to other, possibly 
more effective therapeutic approaches. 
at present, the exact molecular mechanism of action of endostatin is not completely 
elucidated. Endostatin can bind to α5- and αv-integrins on the surface of human endothelial 
cells, thereby inhibiting endothelial cell function.19 also, endostatin can bind to glypican20 
and heparin and heparan sulfate.21 it has been shown that the binding of endostatin to α5β1-
integrin on the endothelial cell surface, results in a simultaneous or subsequent interaction 
with a heparan sulfate proteoglycan and caveolin-1. this interaction leads to an intracellu-
lar signaling cascade, which causes a reduced migratory capacity of the endothelial cell.22 
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furthermore, endostatin has also shown to modulate VEGf and Wnt signaling pathways and 
matrix metalloprotease- 2 activation,2326 which all play an important role in angiogenesis. 
in a previous study we have shown strong inhibitory effects of endostatin on VEGf-
induced migration of human umbilical vein endothelial cells (hUVEcs) in vitro and on the 
growth of the human renal cell carcinoma rc-9 in vivo.6 after subcutaneous implantation 
of the rc-9 tumor in nude mice, we showed regression and inhibition of tumor growth 
after daily administration of endostatin. this effect was most pronounced after 4 days of 
treatment, after which the tumor volume stabilized. 
in order to study the effect and mechanism of action of endostatin, we wanted to 
identify which genes were specically affected by the treatment. for this purpose, the 
human renal cell carcinoma rc-9 was implanted in nude mice and treated with endostatin 
for 4 days, after which we applied the polymerase chain reaction (pcr)-based complemen-
tary Dna (cDna) suppression subtractive hybridization (ssh) technique.27 the ssh-technique 
compares two messenger rna (mrna) populations and identies differentially expressed 
genes in one population. furthermore, we implemented the mirror orientation selection 
(mos)-technique, which signicantly reduces the amount of false-positive genes.28 
in the current work, we show that the endostatin treatment results in an effective 
inhibition of tumor growth, by causing disintegration of blood vessels, thereby generating 
hypoxia and anoxia, leading to tumor cell death. hereafter, applying the ssh-technique 
implemented with the mos-technique, we found several genes to be specically induced 
and several to be suppressed after the endostatin treatment. in order to verify differential 
expression, we studied the histological expression of calpain-2, found to be induced and 
core binding factor a-1/ osteoblast-specic factor-2 (cbfa1/osf2), found to be suppressed after 
endostatin treatment.
Materials and methods
Cell lines, miCe anD intratumoral injeCtion
the cell line rc-9 is derived from a patient with renal cell carcinoma in an advanced stage, 
which forms a solid tumor when transplanted in nude mice. selected rc-9 tumor pieces of 
1mm3 were subcutaneous implanted into the right ank of halothane-anesthetized 6-week-
old balbc nu/nu mice. the human mammary carcinoma cell line mDa-mb-231 was obtained 
from the american type culture collection (rockville, mD, Usa). cells were cultured in 
Dulbecco's modied Eagle's medium (biochrom, basel, switzerland), 10% fetal bovine serum, 
and penicillin/streptomycin (p/s, life technologies, breda, the netherlands) in a humidied 
incubator at 37c at 5% co2. for in vivo injections, cells were grown until 90% conuency 
and dissociated using 0.125% w/v trypsin, 0.05% w/v ethylenediaminetetraacetic acid (EDta) 
solution in pbs (ph 7.2). hereafter, 2106 cells/100 ml pbs/ 10% fcs were injected subcuta-
neously in the right ank of halothane-anesthetized 6-week-old balbc nu/nu mice. after 
approximately 3 weeks, mice having tumors with a volume of 100mm3 were selected and 
divided into two groups. tumor volume was assessed by measuring the two major diameters 
with a caliper and using the formula: tumor volume=/4p/6(d1d2)1/2. the treatment started 
when the tumor volume was approximately 250mm3. recombinant human endostatin was 
obtained from b olsen (harvard, boston, Usa) and was puried for in vivo use in mice as 
described earlier.6 mice bearing rc-9 tumors received daily injections around the tumor of 
2 g human endostatin in phosphate-buffered saline (pbs) during 4 days. the control group 
received injections of pbs alone. mice bearing mDa-mb231 tumors received daily injections 
around the tumor of 200 g endostatin as previously described.29 after treatment, tumors 
were surgically removed and animals were killed. tumors were cut in half, where one half 
was used for rna isolation and one for immunohistochemistry. for rna isolation, tumors 
were suspended in 2ml 4m guanidinium isothiocyanate lysis buffer and stored at -80c until 
further use. for immunohistochemistry, the tumors were xed in zincmacrodex formalin 
(Znmf) xative (0.1m tris acetate (ph 4.5) containing 0.5% zinc-acetate, 5% dextran, and 10% 
formalin) overnight at room temperature.
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immunohistoChemistry
after overnight xation, tissue was washed three times with pbs and subsequently processed 
for parafn embedding. human bone sections were decalcied in 5% sodium EDta for 5 days 
at 4c prior to parafn embedding, as previously described. 30 immunohistochemistry was 
performed on 5 m of Znmf-xed parafn-embedded sections. sections were rehydrated and 
washed with pbs, followed by incubation with 40% methanol/1% h2o2 in pbs for a half an 
hour at room temperature to block endogenous peroxidase activity. after washing with pbs, 
the sections were incubated with 5 g/ml proteinase K in 100mm tris ph 8.0/ 50mm EDta 
ph 8.0 for antigen-retrieval. thereafter, sections were washed twice with pbs, once with 
0.1m tris-buffered saline (ph 7.4) containing 0.02% tween 20 (tnt) and blocked with 0.5% 
boehringer milk protein (bmp) (boehringer, mannheim, Germany) in tnt for 1 h at 37c. this 
was followed by overnight incubation at 4c with the primary antibody, diluted in bmp/tnt. 
the mousespecic rat monoclonal antibody Er-mp12/cD31 that binds to pEcam-1 was kindly 
provided by Dr p leenen (Erasmus University of rotterdam, the netherlands). the mouse-
specic rat monoclonal macrophage antibody f4/80 was a kind gift from Dr p nijweide 
(Department of molecular cell biology, leiden University medical center, leiden, the 
netherlands). the mouse-specic rat monoclonal granulocyte antibody rb6-8c5 that reacts 
with ly- 6G, (also designated Gr-1), was purchased from pharmingen (alphen aan den rijn, 
the netherlands). the goat polyclonal antibody calpain-2 that binds the large subunit of 
calpain-2 and the rabbit polyclonal antibody pEbp2αa (m-70) that binds to pEbp2αa, (also 
designated cbfa1, osf2 and aml3), were purchased from santa cruz biotechnology 
(heerhugowaard, the netherlands). after three washes with tnt, the sections were then 
incubated with biotinylated secondary antibody diluted in bmp/tnt for 45 min at 37c, 
followed by incubation with horseradish (hrp)-conjugated streptavidin (amersham 
pharmacia biotech) diluted in bmp/ tnt for 30 min at 37c. the signal was then amplied 
using biotinylated tyramids as described, 31 followed by incubation with streptavidin hrp 
and nal detection by the chromogen 3- amino-9-ethyl-carbazole (aEc), (sigma chemicals, 
Zwijndrecht, the netherlands). the sections were counterstained with mayer's haematoxy-
lin for 1 min and mounted under glass coverslips with aquamount. representative pictures 
were taken with a nikon Dxm 1200 digital camera. Granulocytes were differentiated on the 
basis of morphology.
the hypoxia marker pimoniDazole
hypoxia in the endostatin-treated tumors was determined as previously described.32 briey, 
mice were intravenously injected via one of the lateral tail veins with 0.1 ml of a solution of 
saline containing 2mg of the hypoxia marker pimonidazole-hydrochloride. this marker was 
given 30 min before the animals were killed. for further analysis, four to ve frozen sections 
(5 m thick) through central and peripheral tumor areas were prepared. hereafter, sections 
were xed in acetone and incubated overnight with rabbit antisera to pimonidazole adducts. 
the sections were then incubated with a uorescent antibody and analyzed for the hypoxia 
signal using uorescence microscopy.
rna anD mrna isolation
rna was isolated from a control and endostatin treated rc-9 tumor according to the method 
described by chomczynski and sacchi.33 in brief, rc-9 tumors were homogenized in 2ml lysis 
buffer, extracted with phenol and chloroform, precipitated at -20c with 100% isopropanol, 
resuspended in autoclaved denatured water, and stored at -80c. rna concentration was 
determined spectrophotometrically assuming 40 g/ml per optical density at a wavelength 
of 260nm (1cm path length). mrna was isolated from control and endostatin-treated rc-9 
tumor rna samples by using the Dynabeads mrna purication Kit in accordance with the 
manufacturer's instructions (Dynal as, oslo, norway).
ssh anD the mos teChnique
ssh was performed using the pcr-selectt cDna subtraction Kit (clontech, heidelberg, 
Germany). in this experiment, a forward and a reverse subtraction was performed. in the 
forward subtraction, mrna of a control rc-9 tumor was referred to as tester and mrna of 
an endostatin-treated rc-9 tumor as driver, and vice versa in the reverse subtraction. in addi-
tion, a control provided in the kit was included. cDna was synthesized from both rc-9 mrna 
samples and the control from the kit (human skeletal muscle mrna) in accordance with 
the manufacturer's instructions. the cDna of the rc-9 tumor samples and the control 
skeletal muscle cDna were digested with Rsai for 1.5 h at 37c. hereafter, digested rc-9 tumor 
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samples were divided in a tester and a driver sample. to produce a control tester, 0.2% haeiii 
digested jx174 Dna was mixed with 1 l of the skeletal muscle cDna. the tester samples 
were ligated with two cDna adaptors. to verify a ligation efciency of at least 25%, a ligation 
efciency test was performed, according to the manufacturer's instructions. subsequently, two 
hybridizations were performed. in the rst hybridization, an excess of driver was added to each 
tester sample. the samples were heat denatured for 1.5 min at 98c and allowed to hybridize 
for 8 h at 68c. the second hybridization consisted of adding freshly denatured driver cDna to 
the two rst hybridization samples. the samples were incubated overnight at 68c. from he-
reon, the ssh-protocol was implemented with the mos-technique as described by rebrikov et 
al.28 briey, each sample was divided into 10 independent samples and a 30-cycle primary pcr 
was performed. the 10 independent samples were then combined and a 12-cycle secondary 
pcr was performed using the same primer and conditions as the primary pcr. a nested 
pcr was performed with primers as described. the samples were then phenol/chloroform 
extracted and ethanol precipitated and adaptors were removed by Xmai digestion. another 
hybridization was performed using freshly denatured driver and a nal pcr was performed.
Dna Cloning
the differentially expressed sequences of the forward and reverse subtraction were cloned 
into a pcrii vector using the ta cloning kit (invitrogen, Groningen, the netherlands). two 
different concentrations of the pcr products, 0.5 and 1.5 l, and 50 ng vector were used in the 
ligation reaction. subsequently, 2 l of each reaction was added to top10f' cells and incubated 
on ice for 30 min. the samples were subjected to a heat shock of 30 s at 42c, 250 l of soc 
medium was added and the samples were incubated at 37c for 1 h. of each sample 10 
and 25 l were plated on luria bertani (lb) plates containing 50 mg/ml ampicillin (roche 
Diagnostics Gmbh, mannheim, Germany), 42 l iptG (20 mg/ml) (Gibco/brl life technolo-
gies), and 80 l x-Gal (20 mg/ml) (Gibco/brl life technologies). the plates were incubated 
overnight at 37c. the white colonies were picked and the inserts were amplied in a pcr using 
m13 primers (Gibco/brl life technologies). the pcr products were puried using microspin 
s-300 hr columns (amersham pharmacia biotech). the puried pcr products were analyzed 
for differential expression by southern blotting. Differentially expressed pcr products were 
sequenced by the leiden Genome technology center (lGtc). the sequences were compared 
to available sequence databases, using basic local alignment search tool (blast).
southern blotting
for probe synthesis, a nested pcr was performed with the unsubtracted controls of the 
forward and reverse subtraction. the products were digested with Rsai for 2 h at 37c and the 
pcr products were puried using microspin s-300 hr columns (amersham pharmacia bio-
tech). thirty ng of each product was denatured for 3 min at 100c and added to ready-to-Go 
Dna labeling beads (amersham pharmacia biotech). thereafter, 5 l α[32p]dctp was added 
and samples were incubated at 37c for 30 min. Unincorporated nucleotides were removed 
by using a probeQuant G-50 micro column (amersham pharmacia biotech). before hybridi-
zation, the probes were denatured for 5 min at 95c and put on ice for 5 min. for southern 
blotting, 50 ng m13 pcr product of each clone was loaded on a 1% agarose gel containing 0.5 
g ethidium bromide. after running, the gels were incubated in 0.4m naoh twice for 15 min. 
hybond-n+ membranes were incubated for 10 min in h2o and for 15 min in 0.4mm naoh. 
Dna was transferred onto the membrane overnight. hereafter, the blots were neutralized in 
2 x ssc for 5 min and incubated at 80c for 30 min. the blots were prewetted in h2o and for 
prehybridization, an equal volume of 2 x Denhardt's hybridization mix (6 x ssc, 5 x Denhardt's, 
0.25% sDs, 50 g/ml denatured fragmented salmon sperm Dna) was added, supplemented 
with 0.5 g/ml denatured Ks cell (a mouse osteoblast cell line) Dna. the blots were prehy-
bridized for 2.5 h at 65c. this was followed by hybridization of the blots overnight at 65c 
with the a[32p]dctp labeled probes of the unsubtracted control of the forward or the reverse 
subtraction. thereafter, the blots were washed in 1 x ssc/0.1% sDs for 20 min, then in 0.3 x 
ssc/0.1% sDs twice for 10 min and in 0.1 x ssc/0.1% sDs for 10 min at 65c. the blots were ex-
posed to a phosphor- imager (molecular Dynamics, sunnyvale, ca, Usa) screen and analyzed.
statistiCal analysis
the data are expressed as mean  s.d. for comparing endostatin-treated rc-9 tumor volumes 
with control tumor volumes, a student's t-test was used. a p-value of <0.05 was considered 
signicant.
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Results
effeCt of enDostatin on rC-9 tumor volume In VIVo
in order to characterize the effect of endostatin treatment and to investigate which genes are 
specically induced and suppressed after the treatment by using the ssh-pcr, rc-9 tumors 
were treated with endostatin or pbs. the human renal cell carcinoma rc-9 was subcuta- 
neous implanted in balbc nu/nu mice. When a tumor volume of approximately 250mm3 
was reached, daily injections of pbs or 0.2 g recombinant human endostatin were adminis-
tered around the tumor during 4 days. this dose and duration have proven to give optimal 
regression in previous experiments.6 figure 1 shows the effect of endostatin-treatment on 
tumor volume. immediately after starting the treatment, the average tumor volume regresses 
compared to the control tumor volume. after 4 days of treatment, the difference in average 
tumor volume is signicant (p<0.05). at day 5, tumors were surgically removed and prepared 
for immunohistochemical analysis and rna isolation.
immunohistoChemiCal analysis of the effeCt of enDostatin on rC-9
to study the effect of endostatin-treatment, we stained rc-9 tumors treated for 4 days 
with mp12 (pEcam-1/cD31), which recognizes endothelial cells and f4/80, which recognizes 
mature macrophages. figure 2a shows an mp12 staining of an endostatin-treated tumor, in 
which mp12 stains the anatomical vessels. figure 2b shows a f4/80 staining of an endostatin- 
treated tumor, in which f4/80 specically stains tissue-macrophages. as can be seen in 
figure 2a, 4-day endostatintreatment results in a necrotic center of the tumor without any 
vessel present (a), whereas the vessels in the outer rim of the tumor remain present after the 
Figure 2 (b) f4/80-stained histological 
section of an endostatin-treated rc-9 
tumor: (a) center of the tumor; (b) outer 
rim of the tumor; (c) f4/80-positive ma-
crophages located as a ring around the 
center of the tumor (magnication: x 100).
Figure 2 (a) cD31-stained histological sec-
tion of an endostatin-treated rc-9 tumor 
obtained after 4 days of treatment. (a) 
center of the tumor; (b) outer rim of the 
tumor, containing blood vessels that stain 
positive for cD31; (c) area around the cen-
ter of the tumor containing disintegrating 
blood vessels. 
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Figure 1 Effect of endostatin-treatment on rc-9 tumor growth in vivo. Effect of endostatin (0.2 g/day, 
open triangles) or pbs (lled squares) treatment on the growth of rc-9 xenografts in nude mice. treat-
ment was started when a tumor had reached a size of 250  20 mm3. tumor volume (mm3) was measured 
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treatment (b). between the necrotic center and outer rim of the tumor, the vessels show a 
loss of integrity as indicated by discontinuation in mp12 staining (c). figure 2b shows that the 
necrotic center of the tumor (a) is separated from the viable outer rim of the tumor (b) by a 
small and distinct border containing a large quantity of tissue-macrophages (c).
CharaCterization of hypoxia in enDostatin-treateD rC-9 tumors
in order to further characterize the effect of the endostatin-treatment on rc-9 tumors after 4 
days, we used pimonidazole as a hypoxia marker. as can be seen in figure 3a, the control rc-9 
tumor shows little or no hypoxia, conrming a well-vascularized tumor. figure 3b shows the 
endostatin-treated tumor. the center of the tumor has no functional vasculature and there-
fore, no pimonidazole-positive hypoxic area is observed. the distinct ring around the necrotic 
center, which contains macrophages and collapsing vessels, however, is strongly hypoxic. the 
outer ring of the tumor, with unaffected vessels, shows no hypoxia as visualized by the 
pimonidazole staining.
Differential gene expression in rC-9 after enDostatin-treatment
in order to examine as to which genes are specically induced and suppressed after the 
endostatin treatment, we performed an ssh using mrna from an endostatin-treated rc-9 
tumor and from a control rc-9 tumor. after performing the ssh, the obtained sequen-
ces of the forward and reverse subtraction were checked for differential expression using 
southern blotting and subsequential hybridization with tester cDna (data not shown), 
before sequencing. since rc-9 is a tumor of human origin, sequences found to be differentially 
expressed may be human or mouse, with human sequences being exclusively expressed by 
tumor cells, and mouse sequences by mouse derived tissue. table 1a shows the genes found 
to be specically induced and table 1b shows the genes being specically suppressed after 
endostatin-treatment in rc-9. in order to conrm differential expression, we examined the 
expression of an apoptosis-related gene, (calpain-2), which we found to be upregulated and a 
bone specic gene (cbfa1/osf2), which was unexpectedly found to be specically suppressed 
after endostatin treatment. the expression of both genes was examined at protein level, by 
using immunohistochemical analysis.
Figure 3 (a) pimonidazole binding in a his-
tological section of a control rc-9 tumor, 
as visualized by uorescence microscopy. 
hypoxic areas are indicated by green 
uorescence light (magnication: x 40). 
Figure 3 (b) pimonidazole binding in a 
histological section of an endostatin-
treated rc-9 tumor, as visualized by 
uorescence microscopy. hypoxic areas 
are indicated by green uorescence light, 
(magnication: x 40).
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sCreening of Differential expression of Calpain-2 in rC-9
in order to verify the differential expression of calpain-2, we used several different control 
and endostatin-treated sections for immunohistochemical analysis. as can be seen in figure 
4a, control rc-9 tumors were negative for calpain-2, whereas sections of endostatin-treated 
rc-9 tumors stained positive for calpain-2 (figure 4b). the positive expression was located to 
tumor cells.
sCreening of Differential expression of Cbfa1/osf2 in rC-9
in order to determine the expression pattern of cbfa1/osf2, which we found to be suppressed 
after endostatin-treatment, sections of different control rc-9 tumors and endostatin-treated 
tumors were used for immunohistochemical analysis. human bone sections were used as 
a positive control (figure 5a). in these sections, osteocytes (a) and bone-lining osteoblasts 
(b) show a positive nuclear staining, in agreement with previous reports.34,35 the bone 
marrow (c) shows no staining. the expression pattern of cbfa1/osf2 was unexpected. 
sections of control rc-9 tumors showed a positive nuclear staining of granulocytes (figure 5b), 
whereas endostatin-treated tumors showed no staining (figure 5c). Endostatin-treated rc-9 
tumors did show to contain granulocytes, when sections were stained with a granulocyte-
specic antibody (figure 5d). as shown in figure 6, the granulocytes we found to stain 
positive for cbfa1/osf2 included neutrophylic granulocytes (a), eosinophylic granulocytes (b) 
and basinophylic granulocytes (c).
Figure 4 (b) calpain-2-stained histological 
section of an endostatin-treated rc-9 tu-
mor (magnication: x 200).
Figure 4 (a) calpain-2-stained histo-
logical section of a control rc-9 tumor 
(magnication: x 200). 
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38PAMSenolc,illivlatnecalpniylnodesserpxE Homo sapiens 0
3-nietorpgnidnibrotcafhtworgekil-nilusnI Homo sapiens 3E-65
esanegordyhedetahpsohp-3-edyhedlarecylgotralimiS Homo sapiens E-134
7622:CGMenolc,1sisopylopnideteledotralimiS Homo sapiens 0
)ZFA2H(Zrebmem,ylimafenotsihA2H Homo sapiens E-174
)2NPAC(tinubusegral)II/m(,2niaplaC Homo sapiens 0
)34545COL(nietorpaDk2.6a Homo sapiens E-133
1esarutasedAemyzneoc-lyoraetS Mus musculus 8E-55
(b) Suppressed genes
Fibronectin Homo sapiens 0
501/67noitces,q12emosomorhC Homo sapiens E-149
ecneuqesAND41emosomorhC Homo sapiens 2E-58
BAC R-944C7 o ibrary RPCI-11 px19-like protein, clone MGC:15370   Homo sapiens 0
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein Homo sapiens E-139
8612:CGMenolc,)atled,esanikesalyrohpsohp(2niludomlaC Homo sapiens 0
0674:CGMenolc,1ahplanilubuT Homo sapiens E-157
ateb,)nietorpG(nietorpgnidnibeditoelcuneninauG Homo sapiens 0
enegaimekueldioleym-diohpmylylbmessanirhtalC Mus musculus 0
)ekil-Inilcicsaf(2rotcafcificeps-tsalboetsO Mus musculus 0
10 days embryo cDNA, RIKEN full-length enriched library, clone:2610016K11 Mus musculus E-117
aDenition of the sequences, as found by comparing sequenced PCR products to available sequence databases using BLAST
(http://www.ncbi.nlm.nih.gov/BLAST).
bThe frequency refers to the number of clones that showed homology with the identical gene found in the sequence database.
cAs human xenografts were used in nude mice, sequences could be reduced to human or mouse origin.
dThe value for the probability that the sequence match is found due to chance.
eNCBI accession numbers of the dened sequences, which can be used to retrieve gene denitions at http://www.ncbi.nih.gov







































Table 1 (a) Induced genes and (b) suppressed genes 4 days after endostatin-treatment of RC-9
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sCreening of Differential expression of Cbfa1/osf2 in mDa-mb231
in order to determine whether loss of cbfa1/osf2- positive granulocytes was restricted to 
endostatin treatment in the rc-9 tumor model, we stained histological sections of endostatin- 
treated mDa-mb231 tumors, which we found to be sensitive to endostatin-treatment as 
well.29 as shown in figure 7, cbfa1/osf2-positive granulocytes were present in control mDa-
mb231 tumors (a) and were absent after endostatin-treatment (b).
Figure 5 (a) cbfa1/osf-2-stained histological section of human bone tissue, with osteocytes (a) and 
bone-lining cells (b) staining positive and bone marrow (c), which is negative (magnication: x 400). 
(b) cbfa1/osf-2 stained histological sections of a control rc-9 tumor, with granulocytes staining positive 
(magnication: x 200). (c) cbfa1/osf-2-stained histological sections of an endostatin-treated rc-9 tumor 
staining negative (magnication: x 200). (d) Granulocytes stained with rb6-8c5 in an endostatin-treated 
tumor. histological section of an endostatin-treated tumor stained with the rb6-8c5 antibody, which 
specically recognizes granulocytes. Granulocytes stain positive, (magnication: x 200).
a b
c d
Figure 6 cbfa1/osf-2-stained histological 
section of a control tumor. magnication of (a) 
a neutrophilic granulocyte (b) an eosinophylic 
granulocyte and (c) a basinophylic granulo-







Figure 7 (a) cbfa1/osf-2-stained histologi-
cal sections of a control mDa-mb231 tumor, 
with granulocytes staining positive (arrows 
indicate cbfa1/osf2-positive granulocytes) 
(magnication: x 200). (b) cbfa1/osf-2 stai-
ning of an endostatin-treated mDa-mb231 
tumor. Endostatin-treated mDa-mb231 tumor, 
stainingnegative Figure 8 cbfa1/osf-2-stained 
histological section of human primary breast 
cancer (magnication: x 200).
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expression of Cbfa1/osf2 in seCtions of human breast CanCer
in order to determine whether cbfa1/osf2-expression was limited to granulocytes found in 
the experimental rc-9 tumor model, we stained several sections of primary tumors and 
lymph node metastases of several patients suffering from breast cancer. We found expres-
sion of cbfa1/osf2 in granulocytes in both primary tumors (figure 8), as well as in lymph 
node metastases. positive granulocytes were found in ve of the nine primary tumors and 
in four of the eleven lymph node metastases stained for cbfa1/osf2. preliminary data show 
no signicant correlation between the expression of cbfa1/osf2 by granulocytes in primary 
tumors or lymph node metastases and prognosis (data not shown).
Discussion
in this study, we have shown that endostatin treatment of human rc-9 xenografts in nude 
mice causes disintegration of blood vessels and subsequent tumor necrosis. Using the 
ssh-pcr combined with the mos-technique, we found several genes to be specically 
upregulated or suppressed by the endostatin-treatment. among others, one gene, that was 
found to be specically suppressed by endostatin, was cbfa1/osf2. cbfa1/osf2 was specically 
expressed in tumor-associated granulocytes. 
previous studies show that endostatin is an effective inhibitor of tumor growth in 
experimental tumor models.6,7,914 in line with these studies, we have shown that endostatin 
inhibits the growth of human renal cell carcinoma rc-9 xenografts in nude mice. We show 
that the endostatin-treatment results in disintegrating blood vessels and hypoxia and anoxia, 
leading to tumor necrosis. this was indicated by a loss of nuclear staining of tumor cells in 
the center of the tumor. furthermore, the center area of the tumor was surrounded by a 
distinct rim of tissue-macrophages, most likely present to remove dead tissue. these obser-
vations are in concordance with previous studies, which show that endostatin can selectively 
induce apoptosis of tumor endothelial cells in vitro and in animals, depriving the tumor of 
oxygen and nutrients and resulting in tumor cell death.5,8,12,13 
applying the ssh-pcr technique combined with the mos-technique, we found eight 
genes to be specically induced and 11 to be suppressed by endostatin-treatment. calpain-2 
(large subunit) was among the genes that were specically induced by the endostatin- 
treatment. calpain-2 (or m-calpain) upregulation has been shown in response to a variety of 
apoptotic stimuli, in various cell types.3639 it has been shown, among others, that calpain-2 
mediates the cleavage of bax, a proapoptotic protein, during drug-induced apoptosis of 
hl-60 cells.40 it has also been shown that calpain activation occurs after cleavage of caspase 
substrates and Dna fragmentation.41 in our experimental conditions, the induction of 
calpain-2 is likely to be the result of the tumor cell apoptosis and death induced by the 
endostatin treatment. fibronectin is an example of a gene that was specically suppressed 
after the endostatin treatment. 
fibronectin is the ligand of α5β1-integrin, which plays an important role in the anti-
angiogenic effect of endostatin.22 it has been shown that endostatin binds to α5β1-integrin in 
an rGD motif dependent manner and competes for the rGD binding sites within bronectin.42 
the mrna levels of bronectin have also shown to be signicantly reduced in wounds of 
endostatin-treated mice43 and in endostatin-treated endothelial cells.44 this is in agreement 
with the specically suppressed mrna levels of bronectin in our model. taken together, 
these data are in favor of a reduced α5β1-integrin interaction with bronectin as a result of 
the endostatin-treatment, which may affect the migration and survival of endothelial cells 
and possibly the tumor cells as well. 
a second gene that was specically suppressed after endostatin-treatment, was cbfa1/
osf2. cbfa1/osf2 (or runx-2, aml-3, pEbp2α-a, or nmp-2) is known as a required transcriptional 
regulator of osteoblast differentiation and bone formation.4547 therefore, our nding of cbfa1/
osf2 expression in granulocytes in control rc-9 tumors was unexpected. cbfa1/osf2 belongs 
to the family of mammalian runt-domain containing factors, consisting of three characte-
rized factors.48 like the two other family members, cbfa1/osf2 was rst thought to play an 
important role in hematopoiesis. surprizingly, few hematopoietic defects were seen in cbfa1/
osf2 knockout mice. mice embryos lacking cbfa1/osf2 had more granulocytes and fewer b cells 
than wildtype embryos.45,46 cbfa1/osf2 knockout mice also demonstrated extramedullary 
hematopoiesis in the spleen and liver due to the congenital absence of bone marrow.49 to our 
knowledge, this is the rst report on expression of cbfa1/osf2 in granulocytes. 
after endostatin-treatment, cbfa1/osf2-expressing granulocytes were no longer 
present in the tumor. neutrophilic granulocytes have reported to be a target for the anti- 
angiogenic effect of angiostatin, another naturally occurring inhibitor of tumor angiogene-
sis.50 furthermore, it has been shown that neutrophilic granulocytes express α5β1-integrins, 
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which can functionally bind to bronectin.51,52 it has been reported that endostatin can 
bind to α5β1-integrins22 and we show here that bronectin is specically suppressed. taken 
together, it is conceivable that the endostatin-treatment has an effect on granulocytes. 
it is important to note that, although cbfa1/osf2- positive granulocytes were absent in 
the tumor after endostatin-treatment, granulocytes were still present. in addition, cbfa1/osf2 
expressing granulocytes were not found in bone marrow of nude mice. Whether cbfa1/osf2 
expression by granulocytes is restricted to a specic subset of tumor-associated granulocytes 
or granulocytes that are, for example, activated by certain inammatory stimuli warrants 
further investigation.
in line with our ndings in the rc-9 tumor model, cbfa1/osf2-positive granulocytes 
were present in non-treated mDa-mb231 tumors and were absent after endostatin treatment. 
this tumor model has previously been shown to be sensitive to endostatin treatment as 
well.29 taken together, this indicates that the loss of cbfa1/osf2-positive granulocytes might 
be a more common phenomenon in response to endostatin-treatment. Whether or not the 
absence of cbfa1/osf2-positive granulocytes is related to the efcacy of endostatin to inhibit 
tumor growth needs further investigation. 
also, we found expression of cbfa1/osf2 by granulocytes in histological sections of 
tumors of patients suffering from breast cancer. cbfa1/osf2-positive granulocytes were both 
found in primary tumors as well as in lymph node metastases; however, preliminary data did 
not show a statistical signicant correlation between cbfa1/osf2 expression in granulocytes 
and disease-free survival or prognosis. the nding of cbfa1/osf2-positive granulocytes in sec-
tions of patients suffering from mammary caricinoma shows that the results obtained are 
not restricted to experimental tumor models alone. 
in summary, we have demonstrated that endostatin causes hypoxia and anoxia 
and tumor cell death in the mouse. Endostatin specically induced and suppressed several 
genes. among other genes, cbfa1/osf2 was specically suppressed by endostatin. Unexpec-
tedly, cbfa1/osf2 was expressed in granulocytes in the tumor. since an effect of different 
anti-angiogenic therapy on granulocytes has been reported before, this might lead to new 
insights in the role of granulocytes in anti-angiogenic therapy in general. the mechanistic 
and functional role of cbfa1/osf2 in granulocytes warrants further investigation.
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Abstract 
in anti-cancer therapy, current investigations explore the possibility of two different 
strategies to target tumor vasculature; one aims at interfering with angiogenesis, the pro-
cess involving the outgrowth of new blood vessels from pre-existing vessels, while the other 
directs at affecting the already established tumor vasculature. however, the majority of in 
vitro model systems currently available examine the process of angiogenesis, while the 
current focus in anti-vascular therapies moves towards exploring the benet of targeting 
established vasculature as well. this urges the need for in vitro systems that are able to 
differentiate between the effects of compounds on angiogenesis as well as on established 
vasculature. to achieve this, we developed an in vitro model in which effects of compounds 
on different vascular targets can be studied specically. Using this model, we examined the 
actions of the fumagillin derivate tnp- 470, the mmp-inhibitor marimastat and the recently 
developed tubulin-binding agent ang-510. We show that tnp-470 and marimastat solely 
inhibited angiogenesis, whereas ang-510 potently inhibited angiogenesis and caused 
massive disruption of newly established vasculature. We show that the use of this in vitro 
model allows for specic and efcient screening of the effects of compounds on different vas-
cular targets, which may facilitate the identication of agents with potential clinical benet. 
the indicated differences in the mode of action between marimastat, tnp-470 and ang-510 
to target vasculature are illustrative for this approach. 
Introducti on
a functioning and continuously expanding vascular network is essential for tumor 
development, growth, survival and metastasis. Given its pivotal role in these processes, 
tumor vasculature is a highly attractive target in anti-cancer therapy. moreover, anti-vascular 
treatment may present with a low risk of developing drug resistance and promises to be 
effective against a broad spectrum of tumors1,2. currently, two key approaches to target the 
tumor's blood vessel network have been developed3,4. one is directed at interfering with 
angiogenesis while the other aims to affect the already established tumor vasculature. 
angiogenesis is the process involving the outgrowth of new blood vessels from 
pre-existing vessels, and many compounds that affect tumor angiogenesis in vitro have been 
identied and are currently being investigated in clinical trials. anti-angiogenic agents that 
have been tested interfere with different targets, such as angiogenic stimuli, receptor activity 
and endothelial cells46. the second approach aims at preferential targeting of the already 
established tumor vascular network and makes use of so-called vascular-disruptive agents 
(VDas)79. all VDas currently examined draw on the differences between tumor and healthy 
vasculature to allow for highly selective targeting of tumor blood vessels10,11. the VDas can 
be divided into two categories: biologic and small-molecule agents (smas). biologic agents 
include peptides and antibodies that deliver effectors to the tumor endothelium, where smas 
exploit the differences between healthy and tumor vasculature to induce selective vascu-
lar dysfunction1214. targeting angiogenesis and already established vasculature could both 
have their role in anti-cancer therapy. Where tumor angiogenesis is well suited for treating 
micrometastatic disease and early-stage cancer, disrupting established tumor vasculature 
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Figuur 1 chemical structure of the tubulin-binding agent ang-510.
leads to rapid vascular collapse, vessel congestion and tumor necrosis and is therefore more 
efcacious against large, already established tumors. both approaches have shown promising 
results in ongoing preclinical studies, but treatments either targeting tumor angiogenesis 
or established tumor vasculature alone are not fully effective10,1519. for this reason, current 
research explores the benet of combining these anti-vascular treatment strategies13,2022. 
When developing new anti-vascular compounds it would be of great benet if one 
could determine if the overall anti-vascular action is mainly due to effects on inhibition 
of angiogenesis or to suppression of established vasculature or a combination of both. 
therefore, in the present study, we developed an assay in which effects of substances on 
angiogenesis can easily be studied next to those on established vasculature in the same in 
vitro model. in order to validate this model system, we examined the actions of a number 
of different anti-vascular agents, among which a recently developed combretastatin like 
tubulin-binding agent ang-510 (fig. 1). 
Materials and methods 
ChemiCals anD reagents 
culture medium was α-mEm from Gibcobrl, breda, the netherlands, supplemented with 
10% fbs and penicillin/streptomycin. rhVEGf-a was from oncogene, sanbio, Uden, the 
netherlands. Er-mp12 directed against murine pEcam-1 (cD31) was kindly provided by Dr. 
p. leenen, Erasmus University, rotterdam, the netherlands. the mmp-inhibitor marimastat 
was kindly provided by chiroscience inc. (cambridge, United Kingdom). tnp-470, a kind 
gift from W. landuyt, University hospital, K.U. leuven, belgium. the newly developed tu-
bulin-binding agent ang-510 was a kind gift from Graeme J. Dougherty and peter D. Davis, 
angiogene pharmaceuticals ltd. (United Kingdom). 
In VItro vasCularization moDels 
In vitro angiogenesis was measured as outgrowth of endothelial capillary structures from 
cultures of 17-day-old fetal mouse metatarsal bone explants, as described previously23. 
in short, isolated metatarsals were cultured for 48 h in 24-well plates in 125 l α-mEm 
medium to allow for attachment to bottom of the culture plate. subsequently, medium was 
replaced by 500 l fresh medium containing VEGf (50 ng/ ml) and the test substances and the 
medium was replaced every 34 days. after a total of 10 days of culture, the explants were 
xed and stained for pEcam-1. 
in the pre-culture experiments, the explants were treated for 24 h with the test 
substances, after attachment to the bottom of the plate, and were subsequently cultured for 
another 10 days in the presence of VEGf (50 ng/ml). 
the area of pEcam-1-positive tubular structures was determined by image analysis 
using image pro plus 3.0 for Windows 95/nt (media cybernetics, carlsbad, ca). images were 
obtained using a digital camera with a xed window of 768 x 576 pixels. Data are depicted as 
number of pixels per area. 
In vitro effects on newly established vasculature were examined in fetal mouse bone 
explant cultures that were rst cultured for 10 days in the presence of VEGf (50 ng/ml) to 
stimulate capillary network formation. subsequently, the medium was replaced with 500 l 
fresh medium containing the test substances and were cultured for another 24 h after which 
they were xed and stained for pEcam-1 and further analyzed as described above. after 
obtaining images for the quantication of pEcam-1 positive structures, the cultures were 
counterstained with mayer's hematoxylin (h) for 30 s and eosin (1% in 96% ethanol) (E) for 
90 s. 
statistiCs 
results are depicted as mean value standard error of the mean (sEm). Differences between 
groups were determined by one-way analysis of variance for multiple comparisons followed 
by fisher's lsD test. 
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Results 
effeCts on angiogenesis 
fig. 2a shows dose-inhibition curves of the effects of marimastat, tnp-470 and ang-510 on 
VEGf (50 ng/ml) stimulated pEcam-1 positive capillary outgrowth from 17-day-old fetal 
mouse metatarsal bone organ cultures. VEGf-stimulated outgrowth was signicantly 
and dose-dependently suppressed by marimastat, tnp-470 and ang-510 with ic50s of 
approximately 0.6, 0.6 and 0.06 m, respectively. the effects of these agents on endothelial 
outgrowth are further illustrated in fig. 2bD. fig. 2b shows a large pEcam-1 positive endothe-
lial network that has been formed after 10 days stimulation with VEGf. fig. 2c and D show 
VEGf- stimulated cultures in the presence of 1 m tnp-470 and 1 m ang-510, respectively. 
both compounds inhibited the outgrowth of a capillary network, with ang-510 being more 
potent than tnp-470. Explants cultured with 1 m marimastat showed inhibition of vascular 
outgrowth, similar to those treated with tnp-470 (not shown). 
in order to study the effect of the three agents in our anti-angiogenic model in more 
detail, we examined the effect of pre-treatment with these agents on subsequent VEGf-
stimulated vascular outgrowth. at time of explantation, pEcam-1 positive endothelial 
precursor cells are located in the perichondrium of the explants, as previously shown23. 
from these precursor cells the capillary structures sprout and form the vascular network. to 
target these precursor cells, directly after adhesion to the culture plate, the fetal bone explants 
were pre-treated for 24 h with the different anti-vascular compounds and were than subse-
quently cultured for 10 days in the presence of VEGf. as shown in fig. 3, pre-treatment with 
marimastat did not affect VEGf-stimulated capillary outgrowth, while both tnp-470 and 
ang-510 signicantly suppressed subsequent VEGf-stimulated outgrowth with ic50 values of 
approximately 0.7 and 0.08 m, respectively. 
Figuur 2 Effects on angiogenesis. (a) 17-day-old fetal mouse bone explants were stimulated for 10 days 
with VEGf (50 ng/ml) in the absence or presence of different concentrations marimastat, tnp-470 or 
ang-510 (n = 6). Quantication of the number of pEcam-1 positive pixels per area is given as mean  sEm. 
**p < 0.01 and *p < 0.05, compared to controls. (bd) Endothelial outgrowth after stimulation with VEGf (b) 





Figuur 3 Effects of pre-treatment on vas-
cular outgrowth. 17-day-old fetal mouse 
bone explants were, directly after adhe-
sion to the culture plate, cultured for 24 h 
with different concentrations of marima-
stat, tnp-470 or ang-510 and subsequent-
ly stimulated for another 10 days with 
VEGf (50 ng/ml) (n = 6). Quantication of 
the number of pEcam-1 positive pixels per 
area is given as mean  sEm. **p < 0.01 and 
*p < 0.05, compared to controls. 
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effeCts on newly establisheD vasCulature 
to study the effects of the three compounds on newly established capillaries, rst endothelial 
outgrowth was stimulated with VEGf (50 ng/ml) for 10 days and subsequently the cultures 
were treated for 24 h with the different anti-vascular agents. as shown in fig. 4a, marimastat 
and tnp-470 did not affect the VEGf-stimulated newly formed vasculature while ang-510 
showed a signicant suppression of newly established vasculature with an ic50 of around 
0.01 m. 
fig. 4b shows control capillary outgrowth after 10 days stimulation with VEGf, stained 
for pEcam-1 and counter stained with hE. fig. 4c and D depicts newly formed vasculature 
after subsequent 24 h treatment with tnp-470 (10 m) and ang-510 (1 m). as shown, tnp-
470 did not affect the established capillary network (similar results were obtained with 
marimastat (10 m) (not shown)). in contrast, 24 h treatment with ang-510 caused a 
signicant disintegration of the newly established capillary structures, with only fragments 
of the original network remaining. histological hE staining revealed that this degenerative 
effect was specic for the capillary network, as the layer of broblastic cells, originating from 
the periosteum on which the capillary network grows and expands23, remained morphologi-
cally fully intact. 
Figuur 4 Effects on newly established vasculature. (a) 17-day-old fetal mouse bone explants were sti-
mulated for 10 days with VEGf (50 ng/ml) followed by 24 h treatment with different concentrations 
marimastat, tnp-470 or ang-510 (n = 6) Quantication of the number of pEcam-1 positive pixels per area 
is given as mean  sEm. **p < 0.01 and *p < 0.05, compared to controls. after culture, bone explant capil-
lary outgrowth was visualized by staining for pEcam-1 in combination with hE. (b–d) the combined 
pEcam- 1 and hE staining are shown for explants stimulated for 10 days with VEGf without subsequent 
treatment (control) (b), and for explants stimulated with VEGf with subsequent 24 h treatment with 
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Discussion 
in this study, we developed an in vitro model that can distinguish between effects of 
compounds on angiogenesis and on newly established vasculature. We examined the effects 
of three anti-vascular agents, among which the recently developed tubulin-binding agent 
ang-510. We showed that this compound effectively interfered with both angiogenesis as 
well as newly established vasculature, whereas the synthetic fumagillin derivate tnp-470 
and the mmp-inhibitor marimastat selectively affected angiogenesis alone. 
angiogenesis is the process of generating new blood vessels from pre-existing 
vasculature, which is indispensable for solid tumor growth and metastasis. as such, targeting 
tumor angiogenesis, in anti-cancer therapy, is an intense eld of interest. current investiga-
tions towards the development of agents that inhibit tumor vascularization, however, not 
only focus on interference with the process of angiogenesis, but also on intervention with 
already established tumor vasculature3,4. compounds that belong to this group are called 
vascular-disrupting agents (VDas); agents that selectively target tumor vasculature on basis 
of structural and functional abnormalities of these vessels 79. in the development of new and 
more effective anti-vascular agents, it is of importance to have model systems available that 
can give accurate information about their mode of action and vascular targets involved and 
thus can differentiate between effects on angiogenesis or newly established vasculature. for 
this, we adapted our previously developed angiogenesis assay consisting of the outgrowth of 
capillaries from cultured fetal mouse metatarsals and suited it to study effects on established 
vasculature as well23. to validate this in vitro model, we examined the effects of three diffe-
rent compounds in several experimental settings. 
We examined the anti-angiogenic actions of two well-known inhibitors of angiogene-
sis, marimastat and tnp-470, respectively, and that of the newly developed tubulin-binding 
agent ang-510. in previous studies, it has been shown that both the synthetic mmp-inhibi-
tor marimastat, as well as the synthetic fumagillin derivate tnp-470 possess strong anti- 
angiogenic properties in various in vitro models by interfering with endothelial cell inva-
sion and proliferation2428. in concordance with these observations, in our model, marimastat 
and tnp-470 potently and dose-dependently inhibited angiogenesis, indicated by suppressed 
outgrowth of pEcam-1 positive capillaries. moreover, the newly developed tubulin-binding 
agent ang-510 also showed strong anti-angiogenic properties in our model system. 
previously, we have shown that pEcam-1 positive endothelial precursor cells are 
present in the perichondrium of the bone explants, before the outgrowth of vasculature23. 
in order to determine whether the observed anti-angiogenic effects might involve a direct 
action on these early-stage endothelial precursor cells from which the capillaries are formed, 
we pre-incubated the bone explants with the different agents for 24 h and subsequently 
cultured them for 10 days in the presence of VEGf. after pre-treatment of the bone explants 
with marimastat, at doses that actively suppressed angiogenesis, there was no effect on the 
subsequent outgrowth of vasculature. recent studies have shown that mmp- inhibitors such 
as marimastat inhibit angiogenesis by blocking the invasion and migration of endothelial 
cells into the extracellular matrix24,29,30, which might explain why in our model, marima-
stat does not have a direct effect on endothelial precursors and their subsequent vascular 
outgrowth after pre-treatment, but strongly inhibits angiogenesis when it is continuously 
present. in line with this, it was previously shown that in a three-dimensional rat aortic 
model, marimastat potently inhibited angiogenesis, without affecting the proliferation of rat 
aortic endothelial cells in monolayer cultures24. 
in contrast to marimastat, tnp-470, and even more potently ang-510, inhibited 
vascular outgrowth after 24 h pre-treatment of the bone explants. tnp-470 is a known 
angiogenesis inhibitor, which has been shown to induce a cell cycle arrest in the G1-phase, 
resulting in inhibition of endothelial cell proliferation and network formation, indicating that 
this compound acts via a cytostatic rather than a cytotoxic mode of action2528. however, in 
our model, at higher concentrations, inhibition of outgrowth of vasculature by tnp-470 was 
not reversible after stimulation with VEGf, suggesting that, at these doses, the mode of action 
is cytotoxic and not cytostatic. interestingly, a similar dual mode of action of tnp- 470 has 
been described on the in vitro growth of human umbilical vein endothelial cells (hUVEcs), 
showing cytostatic inhibition at lower doses and a cytotoxic suppression at higher doses31. 
furthermore, we found that ang-510 strongly inhibited the outgrowth of capillaries after 
pre-treatment of the bone explants, suggesting that this agent possess an irreversible cyto-
toxic mode of action on endothelial precursor cells. this observation is in line with ndings of 
ahmed et al. and iyer et al. who showed that the combretastatin analog a4 phosphate (ca4p) 
was cytotoxic to proliferating hUVEcs6,32. 
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finally, we studied the effects of the three compounds on newly established 
vasculature. in contrast to their actions on angiogenesis, marimastat and tnp-470 did not 
affect newly established capillaries. In vitro studies exploring the effects on established 
vasculature are very rare, however, in one study, using cultures of rat aorta, marimastat 
showed to stabilize rather than to inhibit existing microvessels and to prevent their 
regression, resulting in the prolonged survival of microvascular networks33. to date, no 
studies on the effects of tnp-470 on established vasculature have been published. however, 
our observations, that this agent has no effect on established vasculature may be perceivable, 
since tnp-470 has been shown to act on endothelial cells via a cytostatic action through 
suppression of the cell cycle28. furthermore, as expected, next to its strong inhibitory effects 
on angiogenesis and capillary outgrowth after pre-treatment of bone explants, ang-510 
showed to have a marked disintegrative effect on newly established vasculature. this 
damaging effect of ang-510 was most likely specic for endothelial cells, as concomitant hE 
staining revealed that the underlying layer of broblastic cells remained unaffected. in line 
with our ndings, the VDa ca4p showed in vitro and in vivo rapid disruption of the tubulin 
cytoskeleton and changes in the three-dimensional shape of proliferating endothelial cells3436. 
in conclusion, the current search for more specic and more active VDas is hampered 
by a lack of in vitro models that can accurately distinguish between effects on angioge-
nesis and on established vasculature, urging the need for models which can specically 
differentiate between the two. the overlap in action of VDas on angiogenesis and on 
newly established vasculature illustrates the usefulness of this in vitro model, which is able to 
differentially recognize effects on both vascular targets. this in vitro model provides an 
efcient and rapid way to screen for biological activity of anti-vascular compounds, which 
could prove of great benet in the eld of vascular research. moreover, the ability to make 
a clear distinction between different vascular targets may facilitate the identication of 
pharmacological compounds with potential clinical benet. the indicated differences 
between marimastat, tnp-470 and ang-510 in targeting vascular networks are illustrative 
for this approach. 
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Abstract
non-steroidal anti-inammatory drugs (nsaiDs) and cyclo-oxygenase (cox) inhibitors are 
anti-inammatory agents that have also shown to be useful in anti-cancer therapy. in the 
present study, we show that the specic cox-2 inhibitor celecoxib enhances the inhibitory 
effect of doxorubicin (dox) on human mDa-mb231 breast tumor growth in vivo and in 
vitro. We also found that celecoxib increased the intracellular accumulation and retention of 
dox in vitro. since the nsaiD indomethacin and the specic cox-2 inhibitor ns398 did not 
affect the in vitro actions of dox, these effects are likely to be mediated via a cox-independent 
mechanism. it has been suggested that some cox-inhibitors can enhance the actions of 
cytostatics by overcoming multidrug resistance through the inhibition of abc-transporter 
proteins. however, we found that the three main atp-binding cassette (abc)-transporter 
proteins, implicated in dox transport, were inactive in mDa-mb231 cells. therefore, the nding 
that the p-glycoprotein (p-gp) blocker psc833 also increased cellular accumulation of dox was 
unexpected. in order to unravel the molecular mechanisms involved in dox accumulation, 
we examined the involvement of nf-κb, as this transcription factor has been implicated in 
celecoxib action as well as in chemoresistance. We found that celecoxib and psc833, but not 
indomethacin or ns398, almost completely inhibited basal- and dox induced nf-κb gene-
reporter activity and p65 subunit nuclear translocation. furthermore, the nf-κb inhibitor 
pDtc mimicked the actions of celecoxib and psc833 on cell growth and on intracellular 
accumulation of dox, suggesting that nf-κb is functionally involved in the actions of these 
compounds. in conclusion, we show that structurally different compounds, among which are 
celecoxib and psc833, increase the intracellular accumulation of dox and enhance dox induced 
cytotoxicity in mDa-mb231 breast cancer cells most likely via the modulation of nf-κb 
activity. 
Introduction 
non-steroidal anti-inammatory drugs (nsaiDs) and specic cyclo-oxygenase (cox)-2 
inhibitors are widely used in the treatment of pain and rheumatoid arthritis and have shown 
promising results in the treatment of cancer in experimental and clinical studies.1,2 cox-2 
is overexpressed in many malignancies and is involved in tumor development and growth. 
the effects of nsaiDs and specic cox-2 inhibitors on tumor cells include inhibition of cell 
proliferation, induction of apoptosis and reduction of cell motility and adhesion.210 further-
more, both non-specic and specic cox-2 inhibitors have shown to signicantly inhibit 
tumor angiogenesis.1114 these anti-cancer properties make it worthwhile examining the 
possible benet of combining nsaiDs and cox-2 inhibitors with conventional anti-cancer 
therapies, such as chemotherapy. 
several preclinical and clinical studies have explored and are currently exploring the 
therapeutic benet of combining nsaiDs and specic cox-2 inhibitors with chemothera-
peutics and have been shown to improve treatment outcome. for example, in experimental 
and clinical studies, the cox-2 inhibitor celecoxib has shown to enhance the anti-tumor 
efcacy of several cytostatics, such as that of irinotecan, doxorubin (dox), bleomycin and 
5-uorouracil.1518 the mechanism by which cox-2 inhibitors enhance the action of cytostatics 
is, however, not clear and it is suggested that this may involve mechanisms other than 
suppression of the cox-2 enzyme. for example, it has been proposed that cox-inhibitors 
modulate the resistance of tumors to chemotherapeutic drugs by affecting the activity of 
plasma membrane transporter proteins of the abc-transporter family, which behave as 
energy-dependent efux pumps for cytostatics. the three key mammalian transporters 
involved in the transport of anti-cancer agents, such as the anthracyclines, are p-glycoprotein 
(p-gp/abcb1), multidrug-resistance protein-1 (mrp1/abcc1) and breast cancer resistance 
protein (bcrp/mxr/abcG2).19,20 
in recent years, much effort has been made to identify agents that are able to 
overcome mDr, in order to improve chemotherapeutic treatment. these agents, called 
chemosensitisers, belong to a variety of structural classes, such as calcium channel blockers, 
drug analogues, cyclic peptides and steroids.21,22 it has been suggested that cox-inhibitors 
may also act as chemosensitisers and can overcome mDr by inhibiting p-gp15 or mrps.2326 
however, conclusive evidence for the actions of nsaiDs and specic cox-2 inhibitors on these 
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transporters is lacking. interestingly, apart from mDr, nf-κb has recently been described as 
another cox independent molecular target for actions of nsaiDs and cox-2 inhibitors, such 
as aspirin, indomethacin and celecoxib.2730 moreover, nf-κb has also shown to be involved in 
chemoresistance in different cancer types3136, suggesting a possible role of this transcription 
factor in the chemosensitising effect of cox-inhibitors. 
in the present study, we addressed these issues both in vivo and in vitro by studying 
the effects of nsaiDs, specic cox-2 inhibitors such as celecoxib and specic pump inhibitors 
in combination with dox in the breast cancer cell line mDa-mb231. 
Materials and methods 
Cell lines, ChemiCals anD reagents 
the human mammary carcinoma cell line mDa-mb231 was from the american type 
culture collection (rockville, mD) and was cultured in Dulbecco's modied Eagle's medium 
(biochrom, basel, switzerland) and 10% fcs (p/s, life technologies, breda, the netherlands). 
Dox was from pharmacia b.V., Woerden, the netherlands. indomethacin was from bufa b.V., 
Uitgeest, the netherlands; sc-236, ns-398 and celecoxib were from pharmacia, skokie, Usa. 
psc833 was from novartis, basel, switzerland. probenecid was from sigma, st. louis, mo, 
Usa. Ko143 (fumitremorgan c analogue) was a kind gift from a. van loevezijn, laboratory of 
organic chemistry, University of amsterdam (amsterdam, the netherlands). the uorescent 
pump substrates, syto16 (for pgp), calcein acetoxymethylester (for mrp1) and bodipy-prazosin 
(for bcrp), were from molecular probes, Eugene, or, Usa, and actionomycin D (7-aaD) was 
from pharmingen, san Diego, ca, Usa. for transfections, fugene 6 transfection reagent 
was from roche, basel, switzerland, and the nf-κb reporter construct nf-κb-luc was from 
stratagene, amsterdam, the netherlands, and renilla luciferase (prl-sV40) was from 
promega, madison, Wi, Usa. the nf-κb inhibitor pyrrolidinedithiocarbamate (pDtc) was 
from sigma, Zwijndrecht, the netherlands. 
animal stuDy 
female balb/c nu/nu mice were from iffa credo (l'arbresle, france) and were housed in 
individual ventilated cages under sterile conditions according to the swiss guidelines for the 
care and use of laboratory animals. sterile food and water were provided ad libitum. at start 
of the experiment, the mice were 10 weeks old. mDa-mb231 cells (2 x 106 cells/100 l) were 
injected sc. in the left ank. after 2 weeks, animals containing a tumor with a volume (tV) of 
100  20 mm3 were selected and divided into four groups of eight mice each. tV was assessed 
by using a calliper measuring the two major diameters by the formula tV = p/6 (d1 x d2)1/2. 
mice (8 per experimental group, n = 8) were treated with vehicle (Dmso), celecoxib (15 mg 
kg-1), dox (0.5 mg kg-1) or a combination of celecoxib and dox. all agents were injected i.p. in a 
total volume of 125 l. the mice were treated every other day for 30 days. tV and body weight 
were measured twice a week. 
mts assay 
cell proliferation was assessed by the mts (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4- sulphophenyl)-2h-tetrazolium) tetrazolium assay (cell titer96 aqueous, 
promega). for this, 2 x 103 cells per well were seeded in triplicate in 90 l culture medium in 
96-well at-bottom microculture plates and one day later the additives were added. after 4 d 
of culture, viable cells were determined by adding 20 l mts to each well and measuring oD 
490 (thermomax, molecular Devices) after 2 h incubation. the results were expressed as the 
mean optical density (oD) of each 3-well set. 
Dox aCCumulation assay 
cells (3 x 104) were seeded in 4-well lab-tek glass chamber slides (nalge nunc international 
corp. naperville, il) and incubated overnight after which additives were added for 24 h. 
subsequently, the culture medium was removed and cells were washed three times with pbs. 
cells were xed in 4% paraformaldehyde for 10 min at room temperature, washed three times 
with pbs and mounted under glass coverslips with Vectashield (brunschwig, amsterdam, 
the netherlands). the cells were examined for doxorubicin uorescence using uorescence 
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microscopy. fluorescence was excited at 465495 nm and detected at an emission maximum 
of 515555 nm. intracellular doxorubicin was quantied using computerised image analysis. 
images of control and treated cultures were acquired using a colour ccD camera, digitised 
with a matrix meteor frame grabber, ltered and analysed with image pro plus 3.0. cells (20) 
were measured and values were expressed as mean light intensity per cell  sD, corrected for 
background. 
faCs analysis 
p-gp, mrp and bcrp activities were measured using a green uorescent probe assay with 
specic substrate/modulator combinations as previously described.20,37,38 in short, 3 x 105 cells/
ml were incubated in DmEm at 37c for 4560 min with either: (i) syto16 (0.6 nm) in the 
presence or absence of psc833 (2 m) for p-gp activity, (ii) calcein acetoxymethylester (1 
nm) in the presence or absence of probenecid (3 mm) for mrp1 activity, or (iii) with bodipy- 
prazosin (25 nm) in the presence of psc-833 (2 m) with or without Ko143 (200 nm) for bcrp 
activity. subsequently, they were incubated with 7-amino actinomycin D and ow cytometric 
analysis was performed on a facscalibur (becton Dickinson, san Jos , ca). p-gp, mrp and 
bcrp activities were expressed as ratio of substrate uorescence with modulator present and 
substrate uorescence without modulator present after subtraction of the uorescence of 
the control (cells in accumulation medium alone). since these functional assays are highly 
sensitive, the ratios below 1.52.0 in cell lines are thought to have little practical meaning in 
terms of drug resistance.37,38 
nf-κb reporter assay 
mDa-mb231 cells were seeded at a density of 1.25 x 104 cells/well in 24-well plates, and 
transiently transfected with 1 g of the reporter construct using fugene 6 transfection 
reagent. the nf-κb reporter construct nf-κb-luc was used. to correct for transfection efciency, 
100 ng of renilla luciferase was co-transfected. 24 h after transfection, test substances 
were added to the cells for another 24 h. hereafter, luciferase assays were performed with 
the Dual-luciferase reporter assay system (promega) according to the protocol. cell lysate 
(5 l) was rst assayed for rey luciferase and then for renilla luciferase activity, using the 
Wallac 1450 microbeta trilux luminescence counter (perkinElmer, boston, ma, Usa). firey 
luciferase activity was corrected for renilla luciferase activity. 
western blot analysis 
in all, 10 g of cytoplasmatic or nuclear protein was prepared from cells treated under 
different conditions, separated on 8% sDspaGE and transferred to polyvinylidene diuoride 
membrane by wet blotting. the membrane was blocked for 1 h at ambient temperature 
with 2% milk powder in pbst (pbs containing 0.1% (v/v) tween-20), followed by primary 
antibody incubations (anti-p65 and anti-p50, santa cruz biotechnology, heerhugowaard, the 
netherlands) overnight at 4 c in 0.2% milk powder in pbst. the membrane was washed 
and primary antibodies were detected with rabbit anti-goat igG conjugated to horseradish 
peroxidase and the bands were visualised with enhanced chemiluminescence (amersham 
pharmacia biotech, buckinghamshire, England). hereafter, blots were stripped using blot 
restore membrane rejuvenation kit (chemicon, hampshire, UK) according to the manufac-
turer's instructions. hereafter, protein samples were checked for nuclear and cytoplasmatic 
specicity using anti-lamin a (nuclear membrane structural component, cell signaling 
technology, Usa) and anti-protein disulphide isomerase (pDi, endoplasmatic reticulum 
protein, stressgen biotechnologies, Vic., canada) antibodies. 
statistiCal analysis 
the data are expressed as means  sD for comparing treated groups with control groups, a 
student's t-test was used. a p-value of <0.05 was considered signicant. 
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Results 
mDa-mb231 tumor growth In VIVo 
fig. 1 shows the effects of daily treatment with celecoxib (15 mg kg-1) and dox (0.5 mg kg-1) 
alone or in combination, on the subcutaneous growth of mDa-mb231 human mammary car-
cinoma xeno-transplants in nude mice. after 23 days of treatment, the average tumor volume 
of the mice treated with the combination of dox and celecoxib was, compared to controls, 
signicantly suppressed (p < 0.05). treatment with dox or celecoxib as single agents, with 



















Figuur 1 Effects of celecoxib and doxoru-
bicin, alone and in combination on the 
growth of mDa-mb231 xenografts in nude 
mice. Vehicle (Dmso) (lled squares); 
celecoxib (15 mg kg-1) (open circles); dox (0.5 
mg kg-1) (open diamonds) and celecoxib 
+ dox (lled triangles). Values represent 


























Figuur 2 Effect of dox alone, or in combi-
nation with celecoxib or indomethacin, 
on in vitro mDa-mb231 proliferation (oD 
490). Dox (0.010.5 m) (lled circles); Dox 
+ celecoxib (10 m) (open circles) and Dox 
+ indomethacin (10 m) (open squares). 
results are expressed as treatment ver-
sus control ratio (t/c-ratio); mean  sD *p 
< 0.05 (dox versus dox + celecoxib or 
versus dox + indomethacin).
Figuur 3 Effect of celecoxib on the intracellular accumulation of doxorubicin. (a) shows uorescent mi-
croscopic pictures of mDa-mb231 cells that were incubated for 24 h in a medium containing dox (5 m) 
(A1); (1 m) (B1) or (0.5 m) (C1), or these concentrations of dox in combination with celecoxib (50 m) 
(A2; B2; C2), respectively. magnication: 200x. (b) shows cells treated with dox (1 m) for 24 h, followed 
by 24 h incubation in control medium (A) or medium containing celecoxib (50 m) (B). magnication: 
200x. the bar graphs show, for all experimental conditions, the mean light intensity per cell, measured 



































































































8988 Chapter 4 Celecoxib enhances doxorubicin-induced cytotoxicity in mDa-mb231 cells
mDa-mb231 Cell proliferation In VItro 
fig. 2 shows growth inhibition curves of mDa-mb231 cells by dox in the absence or presence 
of celecoxib (10 m) or indomethacin (10 m). Dox inhibited cell proliferation dose-depen-
dently with an Ec50 of around 0.2 m. co-treatment of the cells with celecoxib, which alone 
had no effect on cell growth, decreased the Ec50 to 0.06 m. in contrast, indomethacin did 
not affect the action of dox, and the same was true for the specic cox-2 inhibitor ns398 (10 
m) (not shown). moreover, the specic cox-2 inhibitor sc236 (10 m), like celecoxib, enhan-
ced the effect of dox, decreasing the Ec50 from 0.2 to 0.08 m (not shown). 
intraCellular aCCumulation anD retention of Dox 
Doxorubicin is an auto-uorescent compound, which enables the visualisation of its intra-
cellular presence by uorescence microscopy. fig. 3a shows the uorescence of intracellular 
accumulated dox in mDa-mb231 cells after incubation for 24 h with different concentrations 
of dox (0.5, 1 and 5 m) in the absence (a1, b1 and c1) or presence of celecoxib (50 m) (a2, b2, 
and c2). as shown in the pictures and in the graphs, the intracellular uorescence, which is 
mainly visible in the nuclei, is at all concentrations signicantly (p < 0.001) higher in cells 
that were co-treated with celecoxib. like celecoxib, the specic cox-2 inhibitor sc236 (50 m) 
also increased the cellular accumulation of dox (not shown). in addition, ns398 (50 m) and 
indomethacin (50 m) did not affect dox accumulation (not shown). fig. 3b shows mDa-
mb231 cells that were incubated for 24 h with dox (1 m) followed by incubation for another 
24 h in control medium (a) or in medium containing celecoxib (50 m) (b), respectively. as 
shown in the pictures and the graphs, cells treated with celecoxib contained signicantly 
(p < 0.001) more dox than those that were incubated in control medium during the second 
24 h culture period. 
effeCts of abC-transporter bloCkers on Dox-suppresseD Cell growth anD on 
intraCellular Dox aCCumulation 
Dox is a substrate for proteins of the abc-transporter protein family that enhance the efux 
of cytostatics. since our results would suggest that celecoxib and sc236 modulate the cellular 
actions of dox via inhibition of these transporters, we examined their possible involvement 
on intracellular accumulation of dox and induction of cytotoxicity in mDa-mb231 cells using 
specic blockers. 
fig. 4 shows a doseinhibition curve of dox in the absence or presence of the p-gp-
blocker psc833 (10 m) on mDa- mb231 growth. psc833 signicantly enhanced the effect of 
dox on cell growth, decreasing the Ec50 from 0.2 m to 0.08 m. moreover, psc833 (50 m) 
markedly increased the intracellular accumulation of dox (not shown). the mrp- blocker 
probenecid (0.15 mm) and the bcrp-blocker Ko143 (110 m) did not affect the cell growth 
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Figuur 4 Effect of dox, alone or in com-
bination with psc833, on in vitro mDa-
mb231 proliferation (oD 490). Dox (0.01-
0.5 m) (lled squares) or Dox + psc833 (10 
m) (open squares). results are expressed 
as treatment vs. control ratio (t/c-ratio); 
mean  sD *p<0.05 (dox vs. dox + psc833). 
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faCsCan analysis for p-gp-, mrp- anD bCrp- transporter aCtivity 
table 1 shows the ratios for the activity of abc-transporters p- gp, mrp1 and bcrp in mDa-
mb231 cells under different treatment conditions. the measured ratio for each of the 
transporters, under all conditions, was hardly different from 1.0 and is considered to reect a 
very low, if any, activity of these proteins since even very low resistant cell lines have a ratio 
of at least 2.0.20,37,38 
effeCts on nf-κb aCtivity 
fig. 5a shows the effects of dox (0.011 m) and celecoxib (0.5 50 m) on nf-κb-luc activi-
ty in mDa-mb231 cells. Dox dose-dependently stimulated nf-κb-luc activity and celecoxib 
dose-dependently inhibited it. fig. 5b shows the effects of celecoxib, indomethacin and the 
p-gp blocker psc833 (all at 50 m) alone or in combination with dox (1 m) on nf-κb- luc 
activity. both celecoxib and psc833 almost completely blocked basal  as well as dox induced 
nf-κb activity, while indomethacin had no effect. in addition, sc236 (50 m) suppressed both 
basal and dox induced nf-κb activity and ns398 (50 m) was totally ineffective (not shown). 
nf-κb p65 anD p50 subunit transloCation 
fig. 6 shows Western blot detection of nf-κb subunit p65 in nuclear (n) and cytoplasmatic (c) 
extracts from mDa-mb231 cells cultured for 24 h in the absence or the presence of different 
additives. as shown, the cytoplasmatic extracts of cells that were cultured in the presence 
of dox (1 m) (lanes 58) stained signicantly stronger for p65 than those cultured in the 
absence of dox (lanes 14). moreover, compared to control (lane 1), celecoxib (50 m) (lane 2) and 
psc833 (50 m) (lane 4) signicantly inhibited nuclear p65 staining, whereas indomethacin 
(50 m) (lane 3) had no effect. furthermore, dox strongly enhanced nuclear p65 staining (lane 
5) which was almost totally suppressed by celecoxib (lane 6) and psc833 (lane 8) and was 
unaffected by indomethacin (lane 7). in addition, no effect of any of the additives on p50 
nuclear translocation was observed, nor on iKKα, iKKβ and iκb-α (not shown). 
Figuur 5 Effects of different additives on nf-kb-mediated luciferase expression (relative light units) in 
mDa-mb231 cells. (a) Dox (0.01-1 m) (black bars) and celecoxib (0.5-50 m) (grey bars). (b) celecoxib, 
indomethacin and psc833 (all at 50 m) (grey bars) alone or in combination with dox (1 m) (black bars). 

















































































































































Figuur 6 Western blot detection of nf-κb 
subunit p65 in nuclear (n) and cytoplas-
matic (c) extracts from mDa-mb231 cells. 
mDa-mb231 cells were cultured for 24 h in 
the absence (lanes 14) or the presence of 
dox (1 m) (lanes 58) and in combination 
with celecoxib (lanes 2 and 6), indometha-
cin (lanes 3 and 7) or psc833 (lanes 4 and 8) 
(all at 50 m).
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Table 1  Activity of Pgp, MRP and BCRP in MDA-MB231 cells.
Pgp-activity MRP-activity BCRP-activity
–cxb +cxb –cxb +cxb –cxb +cxb
Control 1.16 1.00 1.34 1.39 1.13 1.08
Doxorubicin
(0.1 l M)
1.00 1.00 1.29 1.22 1.25 1.25
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effeCts of pDtC on Dox suppresseD Cell growth anD on intraCellular aCCumula-
tion of Dox 
fig. 7a shows the effects of dox in the absence or presence of pDtc (10 m) on mDa-mb231 
growth in vitro, and fig. 7b shows its effect (10 m) on intracellular dox accumulation. as 
shown, pDtc decreased the Ec50 on cell growth from 0.2 m to 0.09 m and also signicantly 
(p < 0.001) increased intracellular dox accumulation, see pictures and bar graph. 
in addition, as expected, pDtc (10 m) inhibited basal and dox (1 m)-induced nf-κb-
luc activity in mDa-mb231 cells from 82  13 to 13  4 and from 163  18 to 39  9 relative photon 
units, respectively (data not shown). Western blot detection of nf-κb subunit p65 in nuclear 
(n) and cytoplasmatic (c) extracts from mDa-mb231 cells cultured for 24 h in the absence 
(lane 1) or the presence of pDtc (10 m, lane 2), doxorubicin (1 m, lane 3), and treatment with 
dox and pDtc (lane 4) shows that pDtc inhibits both basal and dox-enhanced nuclear p65 
staining (fig. 7c). 
Discussion
in this study we show that the specic cox-2 inhibitor celecoxib enhances the cytostatic 
effect of dox on mDa-mb231 tumor growth in vivo and in vitro. celecoxib also signicantly 
increased the intracellular accumulation and retention of dox in vitro. these effects of 
celecoxib were independent of cox-2 and of the activity of the abc-transporters p-gp, mrp1 
and bcrp and were most likely mediated by inhibition of nf-kb. moreover, we show that 
the p-gp blocker psc833, like celecoxib, increased the intracellular accumulation of dox and 
augmented the dox-induced cytotoxicity, independent of p-gp inhibition, mediated most 
likely via suppression of nf-kb activity.
previous studies have shown that nsaiDs and specic cox-2 inhibitors are able to 
enhance the effects of certain cytostatic agents in vitro and in vivo. for example, celecoxib 
was shown to enhance the tumor growth inhibitory effect of dox in breast tumor bearing 
mice15. in line with this, we found that the combined treatment of human breast carcinoma 
mDa-mb231 xenografts in nude mice with dox and celecoxib synergistically inhibited tumor 
growth. In vitro, these compounds also synergistically inhibited the proliferation of mDa-
mb231 cells. the mechanism by which celecoxib as well as sc236 enhanced the action of dox are 
Figuur 7 Effect of dox, alone or in combination with pDtc, on in vitro mDa-mb231 proliferation (oD 490) 
and effect of pDtc on intracellular dox accumulation. (a) Dox (0.0100.5 m) (lled squares); dox + pDtc 
(10 m) (open squares). results are expressed as treatment versus control ratio (t/c-ratio); mean  sD 
* p < 0.05 (dox versus dox + pDtc). (b) fluorescent microscopic pictures of mDa-mb231 cells that were 
incubated for 24 h in a medium containing dox (1 m) (A) or dox in combination with pDtc (50 m) (B). 
magnication 200 x. the bar graph shows, for both experimental conditions, the mean light intensity 
per cell, measured by computerised image analysis, expressed as mean  sD *p < 0.001. (c) Western blot 
detection of nf-κb subunit p65 in nuclear (n) and cytoplasmatic (c) extracts from mDa-mb231 cells. 
mDa-mb231 cells were cultured for 24 h in the absence (lane 1) or the presence of pDtc (10 m, lane 2), 
or in the presence of dox (1 m, lane 3), and dox combined with pDtc (lane 4).
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most likely independent of suppression of cox, as we show that the specic cox-2 inhibitor 
ns398 and the nsaiD indomethacin did not augment the cytotoxic actions of dox. 
some previous studies using less specic or sensitive assays, suggested that the 
enhancement of chemotherapeutic drug efcacy by cox-inhibitors may be due to inhibition 
of the abc-transporters p-gp15 or mrp123-26. in our study, we show that celecoxib and sc236 
augmented the in vitro intracellular accumulation and retention of dox, also suggesting the 
possible involvement of one of the dox transporters in this action. the activity of the key 
transporters of hydrophobic drugs, like the anthracycline dox, namely p-gp, mrp1 and bcrp 
can be inhibited by specic blockers, such as psc833 for p-gp, probenecid for mrp1 and Ko143 
for bcrp, respectively. our results showed that, like celecoxib and sc236, the p-gp blocker 
psc833, but not the mrp-blocker probenecid, nor the bcrp blocker Ko143, stimulated the 
accumulation of dox in mDa-mb231 cells and also synergistically augmented the inhibitory 
effect of dox on mDa-mb231 proliferation. collectively, this would suggest the involvement of 
the p-gp transporter in the actions of celecoxib and sc236 on dox inhibited cell growth and 
intracellular accumulation of dox. however, by using a very sensitive functional assay for p-gp, 
using the uorescent dye syto-1620,38, we showed that the mDa-mb231 cells revealed no p-gp 
activity under all treatment conditions, ruling out its involvement in the actions of celecoxib, 
sc236 and psc833. a nding consistent with this result was reported recently by Wang and 
colleagues39, who showed that abc-transporter proteins were absent in mDa-mb231 cells. 
therefore, another classical mDr phenotype-independent mechanism must be involved in 
the actions of celecoxib, sc236 and psc833 on dox induced cytotoxicity in these cells. 
previously, nf-κb has been shown to be involved in chemoresistance as well as to be a 
molecular target of celecoxib action. it has been shown that constitutive nf-κb activation in 
tumors protects the cells against apoptotic stimuli, such as those induced by chemotherapeu-
tic treatment. Using a transfection luciferase assay, we found that celecoxib could completely 
inhibit nf-κb-luc activity, whereas dox increased it. this is in line with other studies, showing 
that celecoxib can inhibit and dox can specically induce nf-κb nuclear translocation and 
activation of its target genes. in addition we showed that, in contrast to indomethacin and 
ns398, celecoxib, sc236 and psc833 can inhibit basal and dox-induced nf-κb activity. this is 
the rst study that implicates nf-κb as a molecular target for the actions of the p-gp blocker 
psc833. psc833 is in general thought to modulate cellular responses to chemotherapy 
exclusively via the suppression of p-gp drug pumping, although some reports already 
suggested the possibility that pgp-independent effects might be involved in the chemo- 
modulatory action of psc833 on anthracycline cytotoxicity in vitro and in clinical studies.4042 
overall, the nf-κb transfection studies were in complete concordance with ndings 
in the mts and dox intracellular accumulation assays. moreover, Western blot analysis, 
showed that celecoxib, sc236 and psc833 all specically inhibited constitutive and dox 
induced nuclear translocation of the p65 subunit of nf-κb, and not the nuclear translocation 
of the p50 subunit, nor did these compounds affect iKKα, iKKβ and iκb-α. inhibition of p65 
translocation has been implicated in enhancing chemosensitivity of chemotherapeutic 
drugs4345, however, the nding that only p65 is regulated is somewhat unexpected. none-
theless, nf-κb inhibitors, among which are pDtc, have shown to be able to specically 
inhibit nuclear translocation of p65, independently of p50 and in concordance with our 
ndings, sc236 has been reported to suppress p65 nuclear translocation independent of iKK 
activity and iκb-α gene transcription or degradation.46,47 the molecular mechanisms involved 
in this specic regulation of p65 are not well understood, but it is suggested that sc236 may 
directly target proteins that facilitate the nuclear translocation of nf-κb. 
in order to further investigate the role of nf-κb in the observed enhancement of the 
anti-tumor efcacy of dox, we combined the nf-κb inhibitor pDtc with dox in the mts and 
uorescent dox accumulation assays. pDtc, which inhibited basal and dox-induced nf-κb 
activity in our transfection assay, also inhibited basal and dox-enhanced p65 nuclear trans-
location using Western blot analysis and increased the anti-proliferative effect of dox in the 
mts assay as well as the intracellular accumulation and retention of dox. the ability of nf-κb 
activation to induce chemoresistance has previously been related to the escape of apoptosis, 
but the nf-κb pathway is linked to many aspects of cell growth and apoptosis.34,45 our results 
show that the inhibition of nf-κb activation may be involved in modulating intracellular 
chemotherapeutic drug accumulation and/or transport. however, to irrefutably implicate 
nf-κb as the sole and major target in the observed chemotherapeutic drug enhancement, 
further studies are warranted, as pDtc has been shown to not exclusively inhibit nf-κb and 
also to be able to affect the ubiquitinproteasome pathway.48 
Whether the enhanced intracellular dox accumulation is fully responsible for the 
observed, enhanced anti-tumor effect remains to be proven. the molecular mechanism 
linking the inhibition of nf-κb activity with the enhanced dox accumulation and retention may 
be related to membrane-related actions of dox41,49 and is the subject of further investigations, 
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amongst which suppression subtractive hybridisation-pcr50 and micro array studies are 
planned to identify genes and biochemical pathways involved. 
taken together, our results show a new mechanism by which cox-inhibitors can 
overcome anti-cancer drug resistance and enhance chemotherapeutic drug efcacy. the mo-
lecular mechanism by which the inhibition of nf-κb activity enhances the intracellular drug 
accumulation is the subject of further investigations and might have clinical implications. 
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Abstract 
bisphosphonates decrease bone resorption and reduce signicantly the rate of skeletal com-
plications in patients with metastatic bone disease. bisphosphonates have also been shown 
to exhibit anti-tumor activity in vitro but in vivo results have been equivocal. in the present 
study, we investigated the effects of bisphosphonate treatment alone or in combination 
with the cytostatic docetaxel on the growth of breast cancer cells in bone. tumor gowth was 
studied in an athymic nude mice model inoculated with mDa-231-b/luc+ breast cancer 
cells. two days after the inoculation, mice were treated with risedronate, zolendronate or 
docetaxel alone or with a combination of risedronate and docetaxel. bone destruction and 
tumor growth were evaluated radiographically, histologically and by whole-body bioilumines-
cent reporter imaging (bli). five week treatment with high doses risedronate or zoledronate 
(37.5150 g/kg, 5 times/ week), fully protected the bones from osteolysis, but did not affect 
tumor growth. Docetaxel (2, 4, and 8 mg/kg, 2 times/week) inhibited tumor growth dose- 
dependently and after 5 weeks treatment with the highest dose, there was no detectable 
tumor in bone. the combination of a dose of docetaxel (4 mg/kg) that demonstrated only 
a minimal effect on tumor growth, with risedronate (150 g/kg), protected bone integrity 
and nearly completely inhibited the growth of the cancer cells. risedronate and docetaxel act 
synergistically to protect bone and decrease tumor burden in an animal model of established 
bone metastases from breast cancer cells. 
Introduction 
metastatic bone disease is a major cause of morbidity in patients with different cancers 
including those of the breast and the prostate1. Despite differences in the pathogenesis of 
bone metastases from different cancer types, increased osteoclast-mediated bone resorption 
is the major mechanism for tumor-induced bone destruction2, 3. bisphosphonates decrease 
bone resorption and reduce signicantly the rate of skeletal complications in patients with 
metastatic bone disease4. in addition, several in vitro studies reported that bisphosphonates 
have direct anti-proliferative and proapoptotic effects on cancer cells and can inhibit the 
adhesion of cancer cells to mineralized matrices suggesting that these compounds may also 
have a favorable action on the growth and invasive behavior of cancer cells58. however, in 
vivo studies in animal models of bone metastasis have produced equivocal results917. 
these apparently discrepant results regarding an anti-tumor effect of bisphospho-
nates may be related to the timing of interference with bone turnover during the metastatic 
process. Decrease of bone turnover by bisphosphonates before colonization of bone by can-
cer cells, inhibits to a great extent the formation of bone metastases15, 16. however, when 
bisphosphonate treatment is given after the establishment of bone metastases, it has a 
minimal effect on the progression of cancer growth despite a substantial reduction of 
osteolysis. it was hypothesized that cancer cells metastatic to bone after an initial growth 
phase that depends on their interaction with the local stroma, they become independent of 
microenvironment's growth support and progress autonomously15. for the arrest of growth 
of established metastases, compounds with mechanisms of action different from that of 
bisphosphonates will be needed. previous studies with concomitant administration of 
bisphosphonates and chemotherapeutics have shown a reduction in metastatic growth to 
bone1823. however, toxicity of the latter precludes the application of fully effective doses. in 
the present study, we, therefore, tested the hypothesis that doses of a cytostatic that lack 
full anti-tumor efcacy when given alone, can act synergistically with bisphosphonates to 
reduce the growth of bone metastases from breast cancer cells. 
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Material and methods 
Cell line anD Culture ConDitions 
luciferase positive human mDa-mb-231 breast cancer cells (mDa-231-b/luc+), were used for in 
vivo optical imaging as described previously24. mDa-231-b/luc+ cells were cultured in DmEm 
(life technologies, breda, the netherlands) containing 4.5 g/l glucose and supplemented with 
10% fcs (life technologies) and 800 g/ml geneticin/G418 (life technologies). 
animals 
female nude mice (balb/c nu/nu) were purchased from charles river (charles river, maas-
tricht, the netherlands). animals were housed in individual ventilated cages under sterile 
condition, and sterile food and water were provided ad libitum. animal experiments were 
approved by the local committee for animal health, ethics and research of leiden University 
and carried out in accordance with European communities council Directive 86/ 609/EEc. 
experimental animal moDel 
mDa-231-b/luc+ cells were harvested at about 80% conuence after changing to geneticin-
free medium 24 h before inoculation. 
the animals were anesthetized using the isouorane anesthesia system (xGi-
8, xenogen) and a single-cell suspensions of 1.5 x 105 mDa-231-b/luc+ cells/10 l pbs were 
injected into the right tibiae of 6-week old mice as described previously24. 
treatment of the animals started 2 days after intraosseous inoculation of mDa-231-b/
luc+ cells. from this time point (day 0) and during a subsequent period of 5 weeks, they 
received risedronate or zoledronate (5 times per week (100 l by i.p. injection)) (dissolved in 
pbs), docetaxel (2 times per week (50 l by i.p. injection) (dissolved in Dmso) or a combination 
of 5 times per week risedronate and 2 times per week docetaxel concurrently. the control 
animals received vehicle treatment. the different treatment schedules are illustrated in fig. 1. 
bioluminesCent reporter imaging (bli) 
tumor progression of intraosseous growth was monitored weekly by bli. for this, the mice 
were anesthetized as described above and injected i.p. with 2 mg D-luciferin sodium salt 
(synchem ohG) dissolved in pbs, and measurements were done 5 min after the injection of 
D-luciferin. bioluminescence imaging was acquired with a 15-cm foV, a medium binning fac-
tor, and exposure times of 1060 s. imaging data were analyzed by using the program living 
image (xenogen). Values are expressed as relative light units (rlU) in photons per seconds. 
raDiographs 
after the experimental periods, mice were sacriced by cervical dislocation and the tumor 
bearing hind legs were removed and assessed for osteolytic lesions by radiography (Kodak x-
omat tl lm, Eastman Kodak co.) using a hewlett packard x-ray system faxitron 43805 and 
quantied using nih image 1.62b7 software as described earlier25. 
histology 
the skin of the dissected hind legs was removed and the bones were xed for 24 h in pbs with 
4% formaldehyde; subsequently, the bones were decalcied in water containing 10% EDta, 
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Figuur 1 schematic representation of the 
treatment protocol. the left tibial bones of 
nude mice were injected with mDa-231-b/
luc+ cells ('day 0') and 2 days later treat-
ment with i.p. injections of bisphospho-
nate (5 times/week), docetaxel (2 times/
week) or the combination was started. the 
mice were treated for a total of 35 days.
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effeCts of bisphosphonate treatment on metaphysal Dry weight of the tibia 
to determine the effectiveness of bisphosphonate treatment, at the end of the experiment, 
the dry weight of the metaphysis of the right tibia (not inoculated with cancer cells) was 
measured as previously described27. 
Results 
tumor growth kinetiCs 
following inoculation of the left tibiae of athymic nude mice with mDa-231-b/luc+ cells 
there was a progressive increase in tumor size with an increase of the bli signal of more than 
100-fold (1.4  105  2.5  105 to 2.1  107  2.3  107 rlU) from day 7 to 35 (fig. 2a). figure 2b shows 
representative images of the bli signal intensity in the tumor baring leg of a control mouse 
on day 7, 21 and 35, respectively. 
effeCts of bisphosphonates 
We rst examined the efcacy of bisphosphonates on normal bone resorption. for this, 
we measured the dry weight of the metaphyses of contralateral tibiae, which were not 
inoculated with cancer cells, of the animals after 5 weeks of bisphosphonate treatment. 
compared to controls, zoledronate (37.5, 75, and 150 g/kg) and risedronate (150 g/kg) 
(5 times/week) increased signicantly the mean metaphysal weight of the tibae of the mice: 
112.7  19.2 mg (control); 177  13.9 mg (zoledronate 37.5 g/kg); 173.7  19.4 mg (zoledronate 75 
g/kg); 186.1  16.7 mg (zoledronate 150 g/kg) and 155.3  15.0 mg (risedronate 150 g/kg), 
respectively (p < 0.01 for all bisphosphonate doses). the lack of a dose-dependent effect in the 
zoledronate treated animals is due probably to already maximal inhibition of osteoclastic 
Figuur 2 (a) bli measurements of tumor growth in control mice, monitored weekly during the 5-week 
experimental period. results are expressed as individual mouse values. (b) representative biolumines-
cent images of a control mouse at week 1, 3, and 5 after intraosseous inoculation of mDa-231-b/luc+ cells 
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Figuur 3 (a) representative radiographic, histo-
logical and bioluminescent images of a control, 
zoledronate (150 g/kg) and risedronate (150 g/
kg) treated mouse after 5 weeks of treatment. (b) 
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resorption by the lowest dose of this bisphosphonate used. metaphysal weight in the risedro-
nate-treated mice increased to the same extent as that in the zoledronate treated animals, 
indicating that resorption in these mice, was also maximally inhibited. 
both bisphosphonates prevented destruction of the tumor-bearing tibiae, assessed 
radiologically and histologically, but had no effect on tumor growth. 
figure 3 depicts representative radiographs, histological sections and bli pictures 
of the tumor bearing legs, of these mice. radiographically, the proximal tibia of the control 
animal was destroyed, whereas those of the bisphosphonate treated animals were intact, 
indicating protection of osteoclast-induced osteolysis by the bisphosphonates. Goldner 
stained histological sections demonstrated the presence of tumor in the legs of control mice. 
in bisphosphonate-treated mice there was a clear apparent reduction in the tumor within 
the bone whereas treatment had no effect on tumor load outside the bone collar. the bone 
marrow cavity of treated and untreated mice was invaded by the tumor which expanded 
outside the bone collar. obviously, as result of their antiresorptive action, the tibial meta-
physis of the bisphosphonate treated mice contained signicantly more trabecular bone 
than that of controls. the results of bli were consistent with the histological ndings, as 
also shown previously15, 24, and showed no difference in signal intensity between control and 
bisphosphonate-treated animals and neither bisphosphonate at any dose had any effect on 
tumor growth (fig. 3b). 
effeCts of DoCetaxel 
figure 4a shows the effect of systemically administered docetaxel (2, 4 or 8 mg/kg, 2 times/
week) on tumor growth after 5 weeks of treatment. Docetaxel inhibited tumor growth dose-
dependently, with no bli signal being measurable at the highest dose tested. histological 
examination of the tibiae corroborated bli ndings. in contrast to controls, the tibiae of mice 
treated with 8 mg/kg docetaxel were intact and there was no detectable tumor tissue (fig. 4b). 
Qualitative evaluation of the metaphyses revealed further that the amount of metaphyseal 
trabecular bone of docetaxel-treated mice appeared similar to that of controls and less than 
that of bisphosphonate-treated animals after 5 weeks. 
effeCts of CombineD treatment with riseDronate anD DoCetaxel 
to examine the effect of the concomitant administration of bisphosphonate and docetaxel 
on tumor growth, docetaxel was given at minimally effective concentrations (4 mg/kg, twice/
week) and risedronate at a dose of 150 g/kg (5 times/week). as shown in fig. 5a, risedronate 
alone did not affect tumor growth, as expected, while docetaxel alone failed to reduce tumor 
growth in ve of the seven mice. treatment with the combination of docetaxel and risedro- 
nate, however, resulted in a total absence of bli signal in six out of seven mice. histological 
examination conrmed the optical imaging ndings, and only in one animal in the combined 
treatment group a tumor was present whereas in the other six mice no cancer tissue could be 
detected. in addition, like in the mice treated with risedronate alone, the tibiae of the animals 
treated with the combination of docetaxel and risedronate showed no osteolysis and 
contained a large quantity of trabecular bone (fig. 5b). 
Figuur 4 (a) Effect of docetaxel (2, 4, and 8 mg/kg, 2 times/week) on tumor growth after 5 weeks of treat-
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Discussion 
We show here that combined treatment with a potent bisphosphonate and a cytostatic, at 
doses that have minimal effect on tumor growth when given alone, protects skeletal integrity 
and inhibits the growth of breast cancer cells in an animal model of metastatic bone disease. 
animal and human studies have previously shown that increased bone resorption comprises 
the main mechanism responsible for bone destruction in metastatic disease and is related 
to the incidence and severity of skeletal complications in patients with malignancies28, 29. 
breast cancer cells secrete factors, such as pthrp, which stimulate the formation and acti-
vity of osteoclasts leading to bone destruction which causes bone pain, pathological fractures 
and hypercalcemia1, 2, 30, 31. this pathogenetic mechanism provided the rationale for the use of 
bisphosphonates in the management of patients with various tumors which metastasize to 
the skeleton, including those of the breast. however, during bone resorption induced by the 
osteoclasts, factors stored in the matrix of bone are also released in the bone marrow 
microenvironment and can act on cancer cells and stimulate further their growth as well 
as the production of bone resorbing factors2, 31. it was, therefore, thought that inhibitors of 
bone resorption, such as the bisphosphonates, may not only protect the integrity of bone at 
metastatic sites but may also have a favourable effect on the local growth of bone 
metastases. in addition, several in vitro studies have shown that bisphosphonates have 
direct effects on tumor cells, increase their rate of apoptosis, decrease angiogenesis and 
prevent their attachment on bone matrices5, 6. thus, bisphosphonates, in addition, to their 
bone protective effect, may also reduce the growth potential of cancer cells in the bone-bone 
marrow microenvironment. 
this attractive hypothesis has been, however, difcult to prove experimentally or 
clinically and appears to depend on the stage of the metastatic process as well as on the 
techniques used to assess cancer growth. for example, interference with the bone microenvi-
ronment with bisphosphonates before the establishment of bone metastases protects bone 
integrity and inhibits tumor growth. however, when bisphosphonates are given after the 
establishment of bone metastases, their effect on tumor growth is minimal as also shown in 
the present study. furthermore, in studies reporting a benecial effect on the tumor burden 
following bisphosphonate treatment, this is generally evaluated by histology of the area 
contained within the bones of animal models. however, it has been shown that tumor growth 
Figuur 5 (a) Effect of risedronate (150 g/
kg, 5 times/week) and docetaxel (4 mg/
kg, 2 times per/week) treatment, alone or 
in combination, on tumor growth after 
5 weeks of treatment, monitored by bli 
measurement. Difference among groups 
p < 0.001 (one-way anoVa); combination 
therapy (p < 0.001) and docetaxel (p < 0.05) 
different from risedronate alone; combi-
nation therapy different from docetaxel 
alone (p < 0.05). (b) representative biolu-
minescent, radiographic and histological 
images of a control, risedronate (150 g/
kg), docetaxel (4 mg/kg) and risedronate + 
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outside the bone collar was not affected by treatment and that the apparent decrease in tumor 
growth within bone was rather due to the decreased space available due to the preserva-
tion of the bone structure15. such histological ndings were supported by studies which 
assessed directly tumor growth by molecular imaging techniques and showed no effect in the 
overall growth of cancer cells15. We conrmed this in the present study and we showed that 
treatment with the two very potent bisphosphonates risedronate and zoledronate given at 
high doses with similar anti-resorptive potencies to an animal model of established bone me-
tastases were very effective in decreasing bone resorption and preventing bone destruction. 
however, bisphosphonate treatment given alone had only a minor effect on tumor growth 
assessed by histology and bli once the tumor had been established in the bone marrow. in 
contrast, treatment with high doses of docetaxel did not only preserve the structure of bone 
but decreased also signicantly the growth of the cancer cells within and outside the bone 
collar. 
in recent years the signicance of the interactions between tumor cells and cells 
of the bone marrow in the development of micrometastases to overt metastases has been 
increasingly recognized2, 31. in this process, increased bone resorption plays an important 
role and promotes the initial growth of cancer cells. however, once these cells develop into 
macrometastases mechanisms other than bone resorption contribute to their growth 
potential, such as for example angiogenesis. this sequence of events explains why a 
bisphosphonate given to animals for prevention of bone metastases is effective whereas 
when given to models with established metastatic disease has minimal effect on the further 
growth of the tumor. the lack of an anti-tumor effect of bisphosphonates on bone metastases 
in vivo despite the demonstration of such effects in vitro is probably attributed to the specic 
pharmacokinetics of these compounds. bisphosphonates are cleared rapidly from the 
circulation and are taken up preferentially by the skeleton at active remodelling sites where 
they bind strongly to bone32, 33. this action allows only very limited, if any, exposure of the 
cancer cells in the marrow to bisphosphonates34. therefore, for the adequate management 
of established metastatic disease in bone, bisphosphonates may have to be combined with 
other agents which specically affect tumor growth and progression. 
previous studies with bisphosphonates in combination with anti-tumor drugs were 
effective in decreasing tumor growth in relevant animal models and in vitro evidence of a 
synergism has been reported3437. the question, therefore, addressed in this study was 
whether the combination of a bisphosphonate with a dose of a chemotherapeutic that has no 
effect on tumor growth when given alone, might act synergistically on tumor growth in vivo. 
our results showed that a dose of docetaxel that affected tumor growth minimally, when 
dosed alone, had a profound effect on the growth of breast cancer cells in bone when dosed in 
combination with risedronate. in all but one of the treated animals with risedronate and 
the lower dose of docetaxel tumor cells were completely eliminated from bone. thus, the 
combined treatment did not only preserve the structural integrity of bone but had a clear 
anti-tumor effect demonstrated both histologically and by bli. interestingly, trabecular bone 
of the animals treated with risedronate and docetaxel appeared to be better preserved than 
the bone of the animals which received the higher docetaxel dose. this should be attributed 
to the specic action of the bisphosphonate on bone. 
in conclusion, bisphosphonates and chemotherapeutics act synergistically to protect 
bone and decrease tumor burden in an animal model of established bone metastases from 
breast cancer cells. this approach warrants further investigation in animal and human 
studies, as it may allow the use of less toxic dose of chemotherapeutics in the management 
of patients with bone metastases. 
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chapter 6
General discussion 
cancer remains one of the leading causes of death worldwide and as such the development 
of new and improved anti-cancer therapies is of large importance. Despite numerous explo-
rations and ongoing investigations, there still remain therapeutic gaps in the treatment of 
cancer. focus of this thesis is to address and provide further suggestions for lling some of 
these remaining therapeutic gaps, by better understanding some of the molecular changes 
and processes behind the therapeutic treatment with chemopreventive agents (chapter 2), 
using new models to investigate new candidate anti-angiogenic and vascular disruptive 
drugs (chapter 3) and exploring new combination treatment therapies of conventional 
chemotherapeutic strategies together with chemopreventive agents aimed at interfering 
with several important players in tumor development both at the level of the tumor itself as 
its microenvironment (chapter 4 and 5).
1. Differential gene expression in a renal cell carcinoma model after treatment 
with endostatin
chemopreventive agents are being widely explored to interfere with one or more rate 
limiting processes during tumor progression in order to prevent the promotion of tumor 
development at one stage or another. one of the most studied sorts of chemopreventive 
agents are anti-angiogenic agents. as discussed before, anti-angiogenic strategies may 
interfere both with the tumor directly, or with its microenvironment which plays a direct role 
in the further progression, invasion and metastasis of a tumor1. 
in chapter 2, we explored the effect of treatment of the human renal cell carcinoma rc-9 
xenografts in nude mice with the chemopreventive anti-angiogenic agent endostatin. the 
treatment demonstrated to cause signicant disintegration of blood vessels and subsequent 
tumor necrosis. in order to identify the effect of endostatin treatment on a molecular level, 
we applied the pcr based cDna suppression subtractive hybridization (ssh) technique2. the 
ssh-technique compares two mrna populations and identies differentially expressed 
genes in one population. this technique is an all or nothing approach, or in other words, 
this technique allows for the identication of genes that are selectively 'turned on' in one 
population and 'turned off' in the other. further to this, we implemented the mirror 
orientation selection (mos)-technique in the ssh technique, thereby signicantly reducing 
the amount of false-positive genes3. several genes were identied to be selectively induced 
general discussionChapter 6 121120
or suppressed by the treatment as described in chapter 2. amongst the selectively induced 
genes were found calpain 2, insulin-like growth factor binding protein-3 (iGfbp-3), h2a 
histone family member Z; and amongst the selectively suppressed genes were found 
bronectin (fn), tubulin alpha 1 and core binding factor alpha1 (cbfa1).
selective suppression of fn and cbfa1, (also known as osf2, runx-2, aml-3, pEbp2α-a, 
or nmp-2, known as a required transcriptional regulator of osteoblast differentiation and 
bone formation4-6) are further discussed in chapter 2. since the time of publication an 
emerging picture of inammatory processes in the tumor microenvironment has unfolded 
and knowledge in this eld has expanded quite a bit. as such, the ndings as described in 
chapter 2 can now be viewed in a much broader perspective. at time, the downregulation of 
fn could be explained as a direct effect of endostatin treatment as endostatin binds to α5β1-
integrin and fn being the ligand of α5β1-integrin7, 8. this still holds ground to date, however, 
it has further been shown that an indirect effect on the extracellular matrix (Ecm) may have 
at least in part contributed to the suppression of fn9-14.
an important regulator of normal tissue behavior is the Ecm, which surrounds 
cells and is composed of many types of macromolecules. most solid tumors exhibit a very 
different prole of Ecm proteins in the stroma compared to their normal counterparts, and 
many of these proteins interact directly with tumor cells, via integrins and other cell surface re-
ceptors, to inuence functions such as proliferation, apoptosis, migration and differentiation9. 
a number of these proteins are consistently up-regulated in solid tumors, including fn. 
abnormal Ecm remodeling in the tumor's microenvironment during tumor progression 
has been shown to contribute to, or is even required for, tumor formation and progression. 
moreover, it has been shown that interaction of tumor cells with fn can enhance tumor 
survival10, 11. likewise, as noted in the introduction of this thesis, it has been shown that 
'normalization' of the stromal environment should be able to slow or even reverse tumor 
progression12-14. this has actually been shown after anti-angiogenic treatment with VEGf 
antibodies, where normalization of tumor border stroma took place. this normalization was 
found most likely due to a downregulation of matrix-degrading proteases such as mmp9 
and mmp13 in the stroma, leading to a reduced turnover of crucial basement-membrane 
constituents like fn. as such, the specic downregulation of fn as found and described 
in chapter 2 could well be, at least as well, explained by a normalization of the stromal 
environment as induced by the anti-angiogenic treatment15.
as described in chapter 2, the nding of specic suppression of cbfa1 expressing 
granulocytes in untreated tumors was unexpected. it had, however, previously been shown 
that neutrophylic granulocytes can be a target for anti-angiogenesis therapy, because cbfa1 
was reported to be a target for the anti-angiogenic effect of angiostatin, another naturally 
occuring inhibitor of tumor angiogenesis. as for the nding of specic suppression of fn, 
also the role of neutrophilic cells in tumor progression has become more apparent in recent 
years. tumor cells are surrounded by an inltrate of inammatory cells, namely lymphocytes, 
neutrophils, macrophages and mast cells (mcs). in recent years, increased numbers of 
neutrophils in various human tumors compared with healthy tissues have found to be 
present. moreover, their presence has been found to correlate with poor prognosis16-20. 
fitting the emerging picture of tumorigenesis as a kind of inammation process as 
described in the introduction, it is now widely believed that granulocytes play an important 
role in the tumor's microenvironment in the tumor's progression. these cells communicate 
via a complex network of intercellular signaling pathways, mediated by surface adhesion 
molecules, cytokines and their receptors21. results point to the importance of a cross talk 
between several host cells for promoting angiogenic effects in tumor areas. inammatory 
cells cooperate and synergize with stromal cells as well as malignant cells in stimulating 
endothelial cell proliferation and blood vessel formation, tumor proliferation and invasion22-24. 
Granulocytes have been shown to be able to participate in tumor angiogenesis in many ways. 
likewise, inhibition of angiogenesis, normalization of tumor stroma and tumor reduction is 
conceivable and has been shown to be able to block neutrophilic tumor inltration, exactly 
coinciding with our observations22.
the results of chapter 2 further show the importance of the tumor's micro-environ-
ment as a potential therapeutic target as containing many different players contributing 
in the process of tumor progression, such as the Ecm and the inammatory inltrate. as 
mentioned before, anti-angiogenesis therapy has, especially as a single agent, however, 
still live up to the clinical challenge. moreover, cellular and molecular studies indicate that 
signals from the stromal compartment in the tumor's microenvironment play an impor-
tant role in observed acquired resistance of tumors to anti-angiogenic therapy25-27, which in 
earlier years of explorations of anti-angiogenesis therapy was thought to be impossible. one 
of the obstacles herein is, amongst others, that tumors acquire vasculature also via vessel 
co-option from existing vasculature in the microenvironment28. as anti-angiogenic 
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compounds do not affect incorporated pre-existent, or matured tumor vasculature, targeting 
of the existing tumor vessels is explored as an adjuvant approach to accomplish tumor 
regression via disruption of the tumor's blood supply, as is further discussed on in chapter 3.
2. A new model to identify and discriminate between new potential anti-angionic 
drugs and vascular disruptive agents
as described above, therapeutic vascular targeting has so far concentrated almost 
exclusively on anti-angiogenic approaches, which aim to prevent the neovascularization 
process in tumors. current research also explores anti-vascular (vascular-disrupting) 
approaches using vascular-disrupting agents (VDas), aiming to cause the rapid and selective 
shutdown of the established tumor vasculature, leading to secondary tumor-cell death29-33.
VDas are currently rapidly being developed and several clinical trials have been 
carried out or are ongoing34-39. measuring both anti-angiogenic and anti-vascular efcacy, 
but moreover, discriminating between both targets, has proven to be difcult40. this is both 
due to an existing overlap in the effects of VDas and anti-angiogenic agents as a lack of 
well-dened and validated models to study the efcacy of these agents. indeed, some 
anti-angiogenic compounds have shown to cause vasculature remodeling and regressi-
on in vivo41-45 and the VDa combretastatin-a4 phosphate has been described to be toxic to 
proliferating endothelial cells46 and human umbilical vein endothelial cell (hUVEc) migration 
and tube formation in vitro47. the possibility of dening and discriminating between the 
specic effects of different anti-vascular compounds on different targets in vasculature is 
essential in optimizing therapeutic potential. 
in chapter 3, we describe the development of an in vitro model that can distinguish 
between effects of compounds on angiogenesis and/or newly established vasculature. further 
to this, this model allowed us for further specifying anti-angiogenic effects by being able 
to identify the effects of compounds on early stage endothelial precursor cells from which 
capillaries are formed. We examined the effects of three anti-vascular compounds, among 
which the new tubulin binding agent ang-510. We showed this compound to effectively 
interfere with both angiogenesis as well as established capillaries, whereas the synthetic 
fumagillin derivate tnp-470 and the mmp inhibitor marimastat selectively affected angioge-
nesis alone. further to this, where marimastat showed an effect on ongoing angiogenesis, no 
effect on endothelial precursor cells was seen and as such on the onset of angiogenesis. these 
results illustrate the ability of this in vitro model for the specic and efcient screening of the 
effect of compounds on different specic vascular targets, facilitating the identication of 
pharmacological compounds with potential clinical benet.
VDas specically target established tumor vasculature, as it draws on the differences 
in architecture as opposed to its normal counterpart. in tumor vasculature walls are poorly 
developed, often with a discontinuous endothelial-cell lining, there exists a relatively poor 
investiture with vascular smooth muscle cells and there are poor connections between 
pericytes and endothelial cells where the endothelial cells themselves are often irregularly 
shaped, forming an uneven luminal layer, with loose interconnections and focal intercellular 
openings 33, 48-51. it is possible that the cytoskeleton of tumor endothelial cells is particularly 
sensitive to disruption by VDas due to expression of specic tubulin isotypes or posttrans-
lational modications to microtubule associated regulatory proteins52. in non-stabilized 
vasculature, as is often the case in tumor vasculature, tubulin interference causes endothe-
lial cell detachment and subsequent vascular disruption, an effect that is not seen in normal 
stabilized vasculature. the vasculature in the described in vitro model in chapter 3 shows 
similar architectural differences, (i.e. it also lacks smcs and pericytes), which may well 
explain its predictive and discriminatory potential and suit it for studying the effects of 
agents on tumor vasculature.
taken together, these observations also shed new light on the results as described in 
chapter 2. interestingly, one of the selectively suppressed genes after endostatin treatment 
was shown to be tubulin alpha 1. this is further corroborated by recent ndings that endostatin 
is promoting the disassembly of the actin cytoskeleton, disorders in cell-matrix interactions 
and decrease in endothelial mobility53. as such, it would be interesting to see whether the 
anti-vascular effect of endostatin is part of an anti-angiogenic effect, an effect on established 
vasculature as might be conceived based on the results as described in chapter 2, or both. 
one way or another, this further illustrates the existing overlap in actions and effects of anti-
vascular agents, the difculties in dening these effects and as such the need for the in vitro 
model as described in chapter 3. 
the specic targeting of established vasculature provides VDas with a unique and 
promising potential in treating cancer. it seems however inevitable that in order to fully 
exploit the therapeutic potential of these drugs, they need to be combined with other 
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therapies as on their own they leave a viable rim of surviving neoplastic cells at the 
periphery54-56. these residual areas of tumor tissue are believed to survive VDa treatment 
because their nutritional support is derived from vasculature in the adjacent normal tissue 
which can furthermore act as a source of tumor re-growth. as such, VDa treatment alone 
is highly unlikely to totally eradicate the tumor mass. this is corroborated by preclinical 
studies which have concluded that VDas are ineffective at stopping tumor growth when used 
as single agents, and that combination with conventional therapies and/or anti-angiogenic 
therapies should be explored to gain in therapeutic potential and overcome treatment 
refractoriness and resistance as further discussed in chapter 4 and 557-62.
3. Combination therapies in overcoming treatment resistance: enhancing doxoru-
bicin-cytotoxicity by NF-kB-mediated increase of doxorubicin accumulation
as mentioned above and in the introduction of this thesis, it is essential to design better 
and combined strategies to overcome treatment refractoriness and resistance. one of the 
therapeutic areas where resistance plays a major role in achieving full clinical potential is 
chemotherapy. as described in the introduction of this thesis, many different mechanisms 
exist by which tumor cells may become resistant to chemotherapeutic agents and the 
limitations of chemotherapy led to the exploration of chemopreventive approaches. these 
agents alone, however, have not yet provided full clinical benet. Even more, resistance to 
these therapies is now also being observed25. as it points out combinational approaches, 
where more targets are simultaneously inhibited are proving to be an inevitable approach57, 
63, 64. as such, research on combining conventional therapies such as chemotherapeutics with 
chemopreventive agents in order to overcome therapeutic resistance and escape is extensive, 
and includes combining anti-angiogenic agents with chemotherapy.
in chapter 4, we describe the combined effects of the combination of the specic cox-2 
inhibitor and chemopreventive agent celecoxib with the chemotherapautic agent doxorubicin 
on the human breast cancer cell line mDa-mb231 both in vivo as in vitro. it has previously 
been shown that cox-2 inhibitors can signicantly inhibit tumor angiogenesis65-68, but also 
that these agents have an effect on tumor cells directly via inhibition of cell proliferation, 
induction of apoptosis and reduction of cell motility and adhesion69-77. these properties 
provide a rationale for examining the possible benet of combining cox-2 inhibitors such as 
celecoxib with conventional anti-cancer therapies, such as chemotherapy, as is currently also 
being examined in clinical practice78-81. 
combining these agents indeed showed a marked synergistic anti-tumor effect both 
in vivo as in vitro as opposed to applying these agents alone. this effect was found to be most 
likely independent of suppression of cox. interestingly, we showed that celecoxib augmented 
the in vitro intracellular accumulation and retention of doxorubicin via a nuclear 
factor (nf)-kappa-b mediated mechanism. Whereas cox inhibitors have been described as 
chemosensitizers before82-87, chapter 4 describes a new mechanism by which cox-inhibitors 
can overcome anti-cancer drug resistance and enhance chemotherapeutic drug efcacy. 
apart from the direct cytotoxic chemosensitizing effect on tumor cells as described, it is 
known that celecoxib as a cox-2 inhibitor in anti-cancer therapy also targets different 
therapeutic targets in the microenvironment such as on tumor angiogenesis as described 
above, or the inammatory inltrate81, 88-91, which is of large importance as further elaborated 
on in chapter 2. as such, celecoxib may have different therapeutic roles in targeting both the 
tumor as its environment as well.
it has recently been shown that not just the tumor cells themselves contribute to 
chemotherapy resistance, but that the stromal microenvironment might also confer 
resistance to chemotherapy92-95. amongst others, it has been shown that a stroma-related 
gene signature as found by gene expression proling predicts resistance to neo-adjuvant 
chemotherapy in breast cancer. these ndings show further the role the microenvironment 
can play in tumor progression and emphasizes the therapeutic potential of chemopreventive 
agents, as they may have a role not just in overcoming drug resistance to chemotherapy in 
tumor cells directly via an effect on drug transport but may perhaps also indirectly play a 
role via their effect on the stromal environment. taken together, this further emphasizes the 
therapeutic potential of using chemopreventive agents in anti-cancer combination therapy. 
it however also makes clear, that it is possible to address multiple therapeutic targets at once 
with one drug, as is shown for celecoxib.
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4. Combination therapies in overcoming treatment resistance: targeting tumor 
stroma of bone metastases with bone resorption inhibitors
interference with the microenvironmental growth support is not only an attractive 
therapeutic target in primary tumor progression as described above but also in decreasing 
metastatic tumor growth96. tumor cells must lodge, survive, extravasate, become established 
and grow at the secondary site before they become clinically relevant. Each stage is often rate 
limiting and the local microenvironment has a major role in every step in this path.
as touched upon in the introduction of this thesis, the secondary site must contain 
the microenvironment with specic local molecular mediators to support and allow for sur-
vival of the suitable type of cancer cells. this is both dependent on the properties of the tu-
mor cells themselves as on the environment of the site of metastasis. for example, breast 
cancer frequently metastasizes to bone. breast cancer cells themselves already express nu-
merous bone-like properties, or they acquire bone cell-like properties along the way, a pro-
cess which is referred to as osteomimicry97. in expressing these genes, the breast cancer cells 
are well equipped to home, adhere, survive and proliferate in the bone microenvironment. 
next to this, bone contains numerous factors which make it a fertile soil for the survival and 
progression of breast metastases. these factors are continuously released in the environment 
due to osteoclastic bone resorption which is an integral part of the continuous remodeling 
that goes on in bone. the close interaction of the bone environment and breast cancer cells 
in breast cancer metastasis progression is illustrated by the phenomenon of the so-called 
'vicious cycle'. in breast cancer 90% of metastasesin bone were found to express parathyroid 
hormone-related protein (pthrp). pthrp increases osteoclastic bone resorption, with 
consequent release and activation of matrix-integrated growth factors, such as tGf-β and 
iGfs. these factors in turn, stimulate the tumor growth and as such further secretion of pthrp, 
starting the process all over again98.
the essential properties of the miocroenvironment of a tumor's secondary site 
provide a rationale for not just targeting the microenvironment alongside conventional 
cytotoxic therapies in primary tumor development as discussed in chapter 4, but also during 
metastasis. one approach in doing so is by inhibition of chemokines and their receptors, 
which is currently in preclinical and clinical development99, 100. another therapeutic strategy 
is to block the dissemination of tumor cells at the source, by inhibiting the development of 
blood and lymphatic circulatory systems within the tumor. this hypothesis is supported by 
experiments with potent VEGf inhibition101-103. another approach is by direct and specic 
interference with the secondary site, as has been explored amongst others by making use of 
bisphosphonates. bisphosphonates are used clinically for the protection of bone destruction 
by metastases from different primary tumors104-107. the rationale in using bisphosphonates in 
targeting bone metastases lies in their inhibiton of osteoclastic bone resorption and as such 
in interference with the so-called 'vicious cycle' as discussed above.
in chapter 5, we investigated the effects of bisphosphonate treatment alone or in 
combination with the cytostatic agent docetaxel on the growth of breast cancer cells in bone. 
We showed that the bisphosphonate risedronate and docetaxel given at doses that have 
minimal effect on tumor growth when given alone, act synergistically to protect bone and 
decrease tumor burden in an animal model of established bone metastases from breast 
cancer cells. the role of bisphosphonates as an adjuvant treatment in decreasing breast 
cancer metastases has been subject to paradoxal results. in experimental settings, it has been 
shown that bisphosphonate treatment can prevent the establishment of bone metastases 
by using a preventive protocol108, however, clinical studies have shown either a reduction 
of the establishment of new bone metastases, or no effect at all109-111. most recent studies, 
however, point to a favorable effect of using bisphosphonates as an adjuvant treatment in 
primary breast cancer treatment in preventing the development of bone metastatses112. 
these different observations may, however, also be dependent on the potency of the bone 
resorption inhibiton and as such the specic bisphosphonate used.
in treating already established bone metastases from breast cancer, the results 
are emerging to be more apparent. for example, three clinical trials have evaluated the 
potential anti-metastatic efcacy of clodronate in patients with breast cancer. two of these 
trials showed improvements in overall survival (os) and bone metastases free survival in 
patients receiving clodronate113, 114, where long-term follow-up showed improved os at 8.5 
years115. the third trial showed no effect, but this was most probably due to imbalances in 
patient characteristics between the two arms. as such, the use of bisphosphonates is now 
approved for use in metastatic breast cancer disease in the clinical setting116. based on these 
promising results, clodronate is currently being evaluated for preventing bone metastases in 
two large randomized trials (nsabp-b34 and sWoG 0307), and the results are awaited. our 
results as described in chapter 5 add to large and growing body of evidence suggesting 
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benets in an adjuvant setting of bisphosphonates in the treatment of established breast 
cancer metastases in bone. 
Until now, data on the direct anti-tumor effect of bisphosphonates as single agents 
are limited and, thus far, provide conicting evidence. several large randomized clinical 
trials are ongoing with the next-generation bisphosphonate zoledronic acid to prospectively 
conrm an anti-tumor role for bisphosphonates in various tumor types117. our experimental 
results in chapter 5 show that when used in a non-adjuvant setting, when bisphosphona-
tes are given alone after the establishment of bone metastases, the effect on tumor growth 
is minimal. these results are corroborated by studies that show that tumor growth outsi-
de the bone collar was not affected by treatment and that the apparent decrease in tumor 
growth within bone was rather due to the decreased space available due to the preservation 
of the bone structure108. such histological ndings were supported by studies which assessed 
directly tumor growth by molecular imaging techniques and showed no effect in the overall 
growth of cancer cells. We conrmed this in the present study and even more, showed that 
the combination treatment with high doses of docetaxel did also preserve the bone structure. 
these results show, again, as further elaborated on above, that the use of therapeutic agents 
targeting the microenvironment will most likely not be effective as monotherapy in most 
cases, but must be part of combinational therapies.
5. Conclusions and future perspectives
there is an unfolding picture of rate-limiting steps during tumor progression which can 
provide us with numerous potential therapeutic targets. rate-limiting steps during tumor 
progression include for example limitless replicative potential, metastasis the establishment 
of a tumor's vasculature and further on the ability to invade and migrate in surrounding 
tissues. it is becoming increasingly clear both the tumor as its microenvironment contribute 
in these steps. interfering with these rate limiting steps in both the tumor as its microenvi-
ronment via chemopreventive approaches provide us with therapeutic targets for preventing 
tumor progression. in the clinical setting, these approaches are extensively explored, amongst 
others in combination with chemotherapy.
multiple examples of such agents interfering with different steps during tumor 
progression have been described and are being used in preclinical studies and phase iiii 
clinical trials and some in current clinical practice. for example, agents targeting angioge-
nesis include, amongst many others, integrin component antagonists cilengitide, abegrin, 
and Volociximab118-121, the monoclonal antibody against VEGf-a bevacizumab (avastin)122-126, 
a large amount of VEGf tyrosine kinase inhibitors such as semaxinib (sU5416) and 
Vandetanib (aZD6474) both used as rst-line therapy in combination with chemotherapeutic 
regimens for metastatic colorectal cancer127, thalidomide which is by the food and drug 
administration (fDa) and committee for human medicinal products (chmp) approved 
for treatment in multiple myeloma, or the promising new class of agents of soluble VEGf 
receptors, of which aibercept (aVE0005, VEGf-trap) is an apparent example and being 
explored in several phase iii trials in combination with different chemotherapy regimens 
(data from clinicaltrials.gov). 
another example of a class of agents being explored in anti-cancer therapy is VDas, 
targeting the established tumor vasculature, of which combretastatin a4 phosphate is 
the most investigated, being currently explored in several clinical trials in combination 
with chemotherapeutic regimens and chemotherapy together with anti-angiogenesis 
therapy128-131. targets currently which are being explored in the tumor microenvironment 
include interference with the inammatory inltrate, as being explored by using chemokine 
inhibitors99, 100 and cox-inhibitors81, 88-90, interference with matrix degradation by using 
for example mmp inhibitors marimastat and rebimastat133-135 and timps, interference with 
signaling pathways by using signaling and cytokine inhibitors81 and achieving tissue 
and stromal normalization136-138, which is in part the case in the use of bisphosphonates in 
prevention and reduction of breast cancer metastases.
the aforementioned examples are only a small exert of all therapeutic targets 
being explored, where there is an increasing focus in recent years on the role of the tumor 
microenvironment, following the understanding that the alterations that occur in the 
environment around a tumor might prove useful in generating new therapeutic targets. 
it has become clear, however, that using chemoprevention as monotherapy is in the vast 
majority of the cases likely not to be successful. an example of the observed lack of efcacy as 
monotherapy is the observed emerging resistance to anti-angiogenic therapies, which was 
previously thought to be impossible25, 132. as such, most of these targets are explored as part 
of combination strategies. one of the most investigated approaches in these combinational 
strategies is targeting the tumor cells themselves with chemotherapy together with che-
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mopreventive approaches. in this thesis, we explore and address the therapeutic actions and 
potential of chemopreventive agents, either or not as part of a combinational approach with 
chemotherapeutic agents, where the role of the tumor itself and the tumors microenviron-
ment is taken into account. 
future perspectives in exploring anti-cancer combinational strategies lay both in 
expanding the possibilities of conventional therapy by applying old agents in a new fashion, 
as in further exploring chemopreventive appoaches taking into account possible targets in 
the tumor microenvironment as well. for the rst, one area that has not been addressed 
in this thesis is metronomic chemotherapy. metronomic chemotherapy uses conventional 
chemotherapeutic agents as anti-vascular agents. metronomic chemotherapy is dened as 
the chronic administration of chemotherapeutic agents at relatively low, minimally toxic 
doses and with no prolonged drug-free breaks. previous research indicated that the therapeutic 
effect of metronomic chemotherapy is mainly due to a reduction of tumor angiogenesis 
rather than direct cytotoxicity139, 140. in addition, metronomic therapy with the 
chemotherapeutic drug cyclophosphamide selectively depleted t regulatory cells, which are 
key immune regulators in the tolerance and immune avoidance of tumors141, thereby resulting 
in an enhanced tumor immune response142, 143. further to this, the low dosage schedule 
signicantly reduces undesirable toxic side-effects. indeed, this promising and exciting new 
approach to the use of chemotherapy shows promising results in clinical settings144.
another example of new developments is the exploration of a new chemopreven- 
tion strategy in targeting the tumor microenvironment by making use of cancer vaccination 
against target antigens associated with tumor promotion and progression. in vaccinating 
against these antigens, the immune system is used as chemopreventive agent, instead of 
the promoting role it can normally have in tumor development and progression. in the case 
of a successful cancer-related response, antigen-specic t cells will be poised to destroy an 
aberrantly expressed protein even if the host is not exposed until years after the end of 
immunizations. after the abnormal cell is eradicated, t cells will lie in wait for the next 
exposure. the ability to develop effective cancer vaccines for prevention is fast becoming a 
reality as immunogenic aberrant proteins that drive malignant transformation are identied. 
cancer vaccines have shown evidence of efcacy in controlled trials, and the type of 
immune response to a cancer vaccine that will be needed for cancer prevention is becoming 
increasingly known145.
one way or another, applying rational approaches in which cytotoxic agents are 
administered with cytostatic anti-stromal agents hold considerable promise. for example, a 
three-step combinatorial approach could be investigated in which the tumor microenviron-
ment is rst normalized by anti-angiogenic or anti-stromal therapy, followed by treatment 
with cytotoxic therapies to shrink or even eradicate the tumor, then a maintenance regimen, 
such as low-dose chemotherapy or other anti-stromal drugs, could be administered to keep 
any remaining cancer cells in check64. in conclusion, an important step in this direction is the 
recognition that to effectively eliminate cancer, we should also consider targeting the normal 
cells that have been co-opted into supporting them.
the future will, according to the author of this thesis, lie in specic combinational 
therapies targeting both the tumor as its microenvironment, and being tailor made to both 
the tumor as the individual. this personalized regimen will be dependent on the type of 
tumor, the site of development or metastasis, the stage of the disease and gene expression 
patterns of the individual and the tumor itself. in doing so, it would be an attractive possibility 
to target more than one therapeutic area with one and the same agent. as we have shown, 
celecoxib proved to have a chemosensitizing effect on doxorubicin, apart from the previous 
described effects it has on tumor cells directly and the tumor microenvironment such as on 
the inammatory inltrate and malignant progression.
taken together, this thesis explores the use of chemopreventive apporoaches as 
monotherapy and in combinational approaches and explores and discusses their effects 
on both the tumor as the tumor's microenvironment. it shows that these combinational 
approaches hold great promise, if both the role of the tumor as the tumor's microenvironment 
are taken into account as therapeutic targets. Where the term 'magic bullet' has not lived up 
to its promise, perhaps, in the future, the term 'personal strategic weapon's arsenal' could be 
found to t the bill.
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since the discovery of the rst systemic anti-cancer treatments, enormous advances have 
been made in treatment efcacy. Despite these advances, however, cancer remains one 
of the leading causes of death worldwide. one of the most effective and commonly used 
conventional systemic therapies still is chemotherapy, however, both used as single agent 
and in combinational regimens, chemotherapy commonly faces the problem of therapeutic 
resistance. as such, the development of new and improved anti-cancer therapies is of large 
importance. 
the remaining limitations of chemotherapy have led to the exploration of alter-
native anti-cancer approaches such as chemoprevention in order to improve efcacy. 
chemopreventive agents interfere with rate-limiting steps in tumor progression, such as the 
establishment of a functional tumor vasculature. currently, there is a large and unfolding 
picture of rate-limiting steps during tumor progression which can provide us with numerous 
potential therapeutic targets, where it is becoming increasingly clear that both the tumor 
itself and its microenvironment contribute to these steps. interfering with these rate-limiting 
steps in both the tumor and its microenvironment via chemopreventive approaches provides 
us with therapeutic targets for preventing tumor progression. 
in exploring chemopreventive therapies, it is becoming more and more apparent 
that using chemoprevention as monotherapy is in the vast majority of the cases likely not 
to be fully effective. an example of the observed lack of efcacy as monotherapy is the 
observed emerging resistance to anti-angiogenic therapies, which was previously thought to 
be impossible. as such, current research focuses on exploring chemopreventive approaches 
as part of combination strategies. one of the most investigated approaches in these 
combinational strategies is targeting the tumor cells themselves with chemotherapy 
together with chemopreventive agents.
in this thesis, we explore and address the therapeutic actions and potential of 
chemopreventive agents, either or not as part of a combinational approach with chemothera-
peutic agents, where the role of the tumor itself and the tumors microenvironment is taken 
into account. in chapter 2, we used the anti-angiogenic agent endostatin as a treatment for 
human renal cell carcinoma rc-9 xenografts in nude mice and found this to cause signicant 
disintegration of blood vessels and subsequent tumor necrosis. When examining the possible 
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molecular mechanism behind this effect, we found molecular evidence for the involvement 
of different targets within the tumor microenvironment, among others the inammatory 
inltrate by down regulation of a cbfa-1 expressing subset of granulocytes and the extra-
cellular matrix by downregulation of fn. in chapter 3 we addressed the difculty in making 
a distinction between the effect of anti-angiogenic agents and vascular disruptive agents. 
for this we developed a specic new in vitro model which is able to distinguish between the 
onset of angiogenesis via measuring effects on endothelial precursors, ongoing angiogenesis 
and established vasculature. in doing so, this model could provide a great benet in exploring 
the effect of newly developed drugs on tumor vasculature. in chapter 4 and 5, we explored 
the effect of two different treatment options combining a chemopreventive agent with a 
conventional chemotherapeutic agent. in chapter 4 we explored the effect of the chemothe-
rapeutic agent doxorubicin together with the chemopreventive agent and specic cox-2 in-
hibitor celecoxib. We found that celecoxib enhanced the anti-tumor potential of doxorubicin. 
the mechanism behind this was found to be that celecoxib can augment the intracellular 
accumulation of doxorubicin by a nf-kappa-b mediated mechanism. this showed a new 
mechanism by which celecoxib can interfere with tumor progression and provided new 
insights in the additional therapeutic potential of these combinational approaches. in 
chapter 5, we explored the effect of bisphosphonates together with the chemotherapeutic 
agent docetaxel on the establishment of breast cancer metastases in bone. in doing so, 
we found a synergistic effect of using this combinational approach and provided further 
evidence of the favorable role of using bisphosphonates as an adjuvant treatment in 
treatment of breast cancer metastases. this further showed the importance of not just inter-
fering with tumor progression on the level of the tumor itself, but on its microenvironment 
as well.
taken together, this thesis explores the use of chemopreventive approaches as mono-
therapy and in combinational approaches and explores and discusses their effects on both 
the tumor as the tumor's microenvironment. it shows that these combinational approaches 
hold great promise, if taking both the tumor as the tumor's microenvironment into account 
for its potential as therapeutic targets. 
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Samenvatting
ondanks de grote spongen voorwaarts in de behandeling van kanker, blijft kanker wereldwijd 
een van de meest dodelijke ziekten. De belangrijkste systemische therapie in het bestrijden 
van kanker is chemotherapie. sinds de ontdekking van chemotherapie wordt de behandeling 
echter gekenmerkt door resistentieproblematiek, waardoor de ontwikkeling van nieuwe en 
verbeterde therapien van groot belang is. 
De bestaande beperkingen van chemotherapie hebben geleid tot het ontwikkelen 
van nieuwe benaderingen in de behandeling van kanker om behandelingswinst verder uit 
te bouwen. Een van deze benaderingen is chemopreventie. chemopreventie gaat uit van het 
principe dat in de ontwikkeling van een tumor verschillende fases zijn aan te wijzen die van 
essentieel belang zijn in de verdere progressie van de ziekte. Door in te grijpen in een van deze 
fases wordt de verdere progressie van de tumor voorkomen. Een voorbeeld van chemopreven-
tie is anti-angiogenese therapie. De fases die van belang zijn voor een tumor om zich verder 
te ontwikkelen worden steeds duidelijker in kaart gebracht, waarbij het duidelijk wordt dat 
niet alleen de tumor zelf, maar ook de omgeving waarin de tumor zich ontwikkelt bijdraagt 
en ondersteunend is in zijn ontstaan en verdere groei. ingrijpen in een of meerdere van deze 
essentiële fases op zowel het niveau van de tumor als zijn omgeving kan als aangrijpingspunt 
dienen voor nieuwe therapeutische methoden.
chemopreventieve benaderingen hebben als monotherapie tot nu toe nog niet de 
beoogde klinische winst laten zien waarop gehoopt werd. onderzoek richt zich daarom 
meer en meer op het toepassen van combinatie therapien, waarvan chemotherapie met 
chemopreventieve benaderingen een van de meest onderzochte en inmiddels in de klinische 
praktijk toegepaste is.
in dit proefschrift bestuderen we het effect van verschillende chemopreventieve 
middelen al dan niet in combinatie met een chemotherapeuticum, waarbij niet alleen het 
effect op de tumor zelf maar ook op zijn omgeving bestudeerd en bediscussieerd wordt. in 
hoofdstuk 2 tonen we aan dat behandeling met de angiogeneseremmer endostatine de groei 
van een experimenteel niercelcarcinoom in de muis remt door een signicante desintegratie 
van de bloedvaten. Door het onderzoeken van het moleculaire mechanisme werd gevonden 
dat dit onder andere werd veroorzaakt door een effect op de tumoromgeving, waaronder 
een specieke suppressie van het matrixeiwit bronectine en een cbfa1 (core binding factor 
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alpha-1) expresserende subset van granulocyten, onderdeel van het inammatoire inltraat 
in de tumor.
Gezien het feit dat anti-angiogenese therapie nog niet de verwachte therapeuti-
sche resultaten laat zien wordt er steeds meer onderzoek gedaan naar zogenaamde 'vascu-
lar disruptive agents' (VDas). VDas pakken in tegenstelling tot angiogeneseremmers niet 
de ontwikkeling van nieuwe bloedvaten aan, maar zorgen voor de desintegratie van het 
reeds bestaande vaatnetwerk. De ontwikkeling van nieuwe VDas kenmerkt zich door moei-
lijkheden in het maken van onderscheid tussen de effecten van angiogeneseremmers en 
VDas. in hoofdstuk 3 ontwikkelden we een nieuw screeningsmodel waarmee een speciek 
onderscheid tussen het effect van VDas en angiogeneseremmers kan worden gemaakt. Dit 
model is in staat onderscheid te maken tussen verschillende stadia van het ontstaan van een 
vaatnetwerk, zoals de start van het angiogenese proces via te meten effecten op endotheel 
precursors, het doorgaande angiogene proces en het effect op reeds bestaande vasculatuur. 
Dit model zou derhalve een grote rol kunnen hebben in de facalitering van de identicatie, 
nieuwe ontwikkeling en toepasssing van dit soort therapeutica. 
in hoofdstuk 4 en 5 wordt er verder ingegaan op de toepassing van combinatietherapien 
van chemopreventie middelen met chemotherapeutica en de toepassing en het effect van 
deze combinatie op de tumor en zijn omgeving. in hoofdstuk 4 wordt het effect van het 
chemopreventieve middel celecoxib onderzocht op de groei van mammacarcinoom in 
combinatie met het chemotherapeuticum doxorubicine. in dit hoofdstuk laten we zien 
dat celecoxib het effect van doxorubicine speciek kan versterken, door een nf-kappa-b 
gemedieerde verhoging van de intracellulaire opname van doxorubicine. Deze nieuwe 
bevinding onderstreept de verscheidene mogelijkheden en therapeutische facetten in de 
toepassing van chemopreventieve middelen.
in hoofdstuk 5 werd het effect van een combinatie van een bisfosfonaat, een 
botresorptieremmer, met het chemotherapeuticum docetaxel onderzocht op bestaande 
botmetastasen van mammacarcinoom. We toonden een synergistisch effect aan in de 
toepassing van de combinatietherapie, welke eens te meer aantoonde dat het niet alleen van 
belang is om de tumor zelf te remmen maar tevens in te grijpen op de omgeving waarin hij 
zich ontwikkelt.
samenvattend onderzochten we in dit proefschrift het therapeutisch effect van 
chemopreventie benaderingen, zowel als monotherapie als in combinatietherpaie met 
een chemotherapeuticum. het laat zien dat dit soort combinatietherapie een grote belofte 
in de behandeling van kanker is, waarbij zowel de rol van tumor zelf maar ook die van zijn 
omgeving waarin hij zich ontwikkelt niet onderschat moet worden en van groot therapeu-
tisch belang en potentieel is.
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List of abbreviations
6-mp   6-mercaptopurine
abc   atp-binding cassette
aEc   amino-9-ethyl-carbazole
all   acute lymphoblastic leukaemia
bcrp   breast cancer resistance protein
blast   basic local alignment search tool
bli   bioluminescent imaging
bmp   bone morphogenetic protein
bsp   bone sialoprotein
ca4p   combretastatin-analogue a4 phosphate
caf   cancer-associated broblast
cbfa   core binding factor alpha
cDna   complementary Dna
chmp   committee for human medicinal products
cox   cyclo-oxygenase
csc   cancer stem cell
Dhfr   dihydrofolate reductase
Dmso   dimethylsulfoxide
Dna   deoxyribonucleic acid
Dox   doxorubicin
Ec50   50% effective concentration 
Ecm   extracellular matrix
EDta   ethylenediaminetetraacetic acid
Emt   epithelial mesenchymal transition
fDa   food and drug administration
fGf   broblast growth factor
fn   bronectin
hUVEc   human umbilical vein endothelial cell
il   interleukin
iGf   insulin growth factor
iGfbp   insulin-like growth factor binding protein
iKK   i kappa b kinase
inf   interferon
lGtc   leiden genome technology center
mc   mast cell
mDr   multi-drug resistant
mmp     matrix metalloproteinase
mos   mirror orientation selection 
mrna   messenger rna
mrp   multi-drug resistant associated protein
mts   3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
   (4-sulfophenyl)-2h-tetrazolium
nf   nuclear factor
nsaiD   non-steroidal anti-inammatory drug
oD   optical density
os   overall survival
opn   osteopontin
pbs   phosphate buffered saline
pcr   polymerase chain reaction
pDGf   platelet-derived growth factor
pDtc   pyrrolidinedithiocarbamate
p-gp   p-glycoprotein
plGf   placental growth factor
pmn    polymorphonuclear cell 
pthrp   parathyroid hormone-related protein
ranKl   receptor activator of nuclear factor kappa b ligand
rlU   relative light units
rna   ribonucleic acid
sD   standard deviation
sEm   standard error of the mean
sma   small molecule agent
smc   smooth muscle cell
153152 Chapter 7 summary, samenvatting, list of abbreviations, acknowledgements, curriculum vitae, list of publications
ssh   suppression subtractive hybridization
t/c   treatment vs control
tGf   transforming growth factor
timp   tissue metalloproteinase inhibitor
VDa   vascular-disruptive agents
VEGf   vascular endothelial growth factor
Znmf   zinc-macrodex formalin
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Dankwoord
Graag dank ik iedereen die in welke mate dan ook heeft bijgedragen aan de totstandko-
ming van dit proefschrift. Gedurende mijn aanstelling aan de afdeling Endocrinologie en 
stofwisselingsziekten, maar ook in mijn huidige baan bij het college ter beoordeling van 
Geneesmiddelen zijn er vele collega's geweest die het schrijven van dit proefschrift mogelijk 
hebben gemaakt. 
De volgende mensen wil ik graag speciek bedanken. clemens, zonder jouw enthousiasme, 
stimulans, maar met name ook geduld (5 jaar is toch best lang), zou de promotie nooit 
hebben plaatsgehad. heel erg bedankt. Ermond, dank voor alle hulp bij het opzetten van de 
experimenten en het schrijven. Daarnaast mijn ouders en Josine: zonder jullie was dit nooit 
gebeurd. 
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Curriculum Vitae
De auteur van dit proefschrift werd 14 april 1977 geboren te purmerend. na het behalen van 
het gymnasium diploma aan het newman college te breda in 1995, begon hij in datzelfde 
jaar aan de opleiding biomedische Wetenschappen aan de Universiteit leiden alwaar in 
2000 het diploma werd behaald. Datzelfde jaar begon hij aan het onderzoek op de afdeling 
Endocrinologie en stofwisselingsziekten van het leids Universitair medisch centrum onder 
leiding van prof. dr. c.W.G.m. lwik wat uiteindelijk heeft geleid tot de behaalde resultaten 
als beschreven in dit proefschrift. Dit onderzoek werd onder andere genancierd door de 
nederlandse organisatie voor Wetenschappelijk onderzoek (nWo, beurs: pGn 902-17-090) 
en het Koningin Wilhelmina fonds (KWf, beurs: rUl2000-2196). Vanaf 2007 is hij werkzaam 
als regulatory project leader (rpl) bij het college ter beoordeling van Geneesmiddelen, waar 
hij sinds 2010 als senior rpl zijn werkzaamheden voortzet.
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